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1. Introduction  
Coagulation and inflammation are the interdependent processes attributed to the host 
defence response to injuries. A synchronized activity of both pathways represents an 
essential prerequisite for restitution of host homeostasis after ultimate disturbances of the 
latter. Crosstalk between coagulation and inflammation is considered to inherit from 
primitive coagulation systems similar to invertebrates. For instance, in Horseshoe “crabs” 
(Limulus) coagulogen, a clotting protein with the bactericidal function, and coagulation-
related serine proteases are both located in circulating hemolymph cells (hemocytes) and are 
capable of simultaneously protecting against injury, as well as to isolate pathogens within 
cysts (Tanaka et al., 2009). In humans, the complement system as a part of innate immunity 
remains closely related to the hemostasis system (Markiewski et al., 2007). The organizations 
of these two systems demonstrate several similarities of both structural and functional 
features. Both systems are organized into proteolytic cascades; serine proteases of the 
chymotrypsin family are the components of the latter. Proteases of each system are, in their 
molecular structure, glycoproteins, which have a highly conservative catalytic site 
composed of serine, histidine, and aspartic amino acid residues. These proteases exist in the 
form of inactive zymogens and are subsequently activated by upstream, active proteases. 
Proteins of the complement and hemostasis systems are mostly synthesized in the liver by 
hepatocytes, besides being additionally produced during an acute-phase response 
stimulated by common inflammatory mediators. The biological role of the complement 
system is mentioned here in order to note that the above-mentioned similarities represent a 
forcible argument in favour of the common origin of both immunity and hemostasis 
phenomena. The complement system has been described in detail recently (Castellheim et 
al., 2009; Markiewski et al., 2007) and will not be further discussed here. Though, it is 
worthwhile to mention that the blood hemostasis system in humans, hypothetically, has 
been evolved progressively from the archaic innate immunity organization, diverging to 
certain narrow-specific pathways, which are responsible for the coagulation control.  
Hemostasis in humans is organized as closely interrelated enzyme cascade systems: (i) fibrin 
clotting system (coagulation); (ii) multilevel system for preventing uncontrolled fibrin 
formation (anticoagulation); and (iii) system for limiting the amount of cross-linked fibrin 
(fibrinolysis). Together, coagulation, anticoagulation and fibrinolysis are associated into a 
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self-regulated and highly organized molecular machine that provides either acceleration or 
reduction of blood hemostasis process (Spronk et al., 2003). Accurate regulation of the 
coagulation rate is an effective mechanism, preventing circulatory disorders. This regulatory 
mechanism is known to be a part of the acute phase of the inflammatory reaction which 
provides rapid restoration of physiological homeostasis. 
Hemostasis is closely linked to innate immunity and inflammation through particular 
regulatory coupling like protein C system (Fig. 1). Cooperation between hemostasis and 
innate immunity facilitates injury recognition, vessel wall reparation, and prevention of 
excessive bleeding without causing thrombosis. These processes are mediated by a balance 
of cellular surface components, cell-derived factors, and soluble plasma proteins (SPPs). 
After interruption of the vascular integrity, concentrations of some hemostatic SPPs (HSPPs) 
change in a manner typical of those of acute-phase proteins (APPs). In agreement with 
definition of APPs (Kushner & Rzewnicki, 1994; Morley & Kushner, 1982), at least several 
HSPPs including fibrinogen, plasminogen, and PAI-1 should also be classified as APPs, 
since: (i) the intensity of synthesis of these HSPPs dramatically changes (by more than 50%) 
during pathological processes (ii) HSPPs synthesis in hepatocytes during the acute-phase 
response are regulated by inflammatory-associated cytokines; (iii) due to chronic 
stimulation by inflammatory mediators, HSPPs may persist in circulation and participate in 
the formation of a “semantically paradoxical chronic acute-phase response” (Gabay & 
Kushner, 2001). The above-indicated similarities between inflammation and hemostasis 
determine their unidirectional changes. These changes involve pro-coagulant activities of 
inflammatory processes, as well as the pro-inflammatory efficacy of the hemostatic 
molecular machine.  
 
 
 
Fig. 1. Schematic representation of the protein C-dependent cross-point between hemostatic 
and inflammatory pathways. Diagram illustrates a putative regulatory mechanism, 
maintaining homeostasis within physiological limits. Both pathways are balanced by the 
PC/APC (protein C/activated protein C) system, directly by attenuation of production of 
thrombin as a pro-inflammatory and pro-coagulant agent, or indirectly, by controlling NF-
kB-dependent anti-inflammatory pathways through EPCRs (endothelial protein C 
receptors) and PARs (protease-activated receptors) at the surface of the target cells. See the 
text for discussion in detail. 
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The capacity of inflammatory mediators to regulate hemostasis, as well as some aspects of 
the coagulation ability to affect inflammatory events have been extensively reviewed 
(Butenas et al., 2009; Danese et al., 2010; Esmon, 2005; Jennewein et al., 2011; Levi et al., 2004; 
Medcalf, 2007). Reciprocal regulation of gene expression is the most important mechanism, 
by which inflammatory and hemostatic pathways interact with each other. The role of cell 
surface receptors in providing APP-associated signalling has been recently elucidated 
(Busso et al., 2008; Guitton et al., 2011). The role of the increased HSPPs in the regulation of 
hemostasis and inflammation pathways under pathophysiological conditions, however, 
remains less clear. The molecular mechanisms, responsible for the influence of inflammation 
upon hemostasis and vice versa, remain largely unknown. We would like to review here the 
most important post-translational events, which might perturb HSPPs structure and 
functions, as well as those influencing measurable levels of HSPPs during inflammation.  
2. Cooperation of inflammatory and hemostatic pathways during acute phase 
response 
In normal conditions, HSPPs are presented by a soluble fibrous protein, fibrinogen, 
abundant serine protease zymogens (inactive enzymatic precursors), and minute amounts of 
active proteases, as well as by non-enzymatic cofactors and protease inhibitors (Table 1).  
 
Precursor conversion HSPP 
identification 
The basic 
function in hemostasis 
Proteolytic 
activation 
Expression 
during the 
acute-phase 
response 
Clotting factors  
Fibrinogen (Fg) → 
fibrin (Fn)  
a fibrous 
(structural) 
protein 
substrate for 
polymerization to fibrin 
that is important in tissue 
repair
by thrombin 
 
increase, 
1,5-4,0-fold 
Prothrombin (II) → 
thrombin (IIa) 
trypsin-like  
serine protease 
(endopeptidase)
the conversion of Fg to Fn 
leading to the formation 
of a fibrin clot 
by 
prothrombinase
no change or 
weak increase 
Factor V (V) →  
activated factor V (Va)
ceruloplasmin-
like binding 
protein  
as a cofactor for Xa 
participates in thrombin 
activation, not 
enzymatically active
 
by thrombin 
 
 
ND 
Factor VII (VII) →  
activated factor VIIa 
(VIIa) 
serine protease 
(endopeptidase)
the catalytic component of 
the extrinsic tenase, 
activates IX to IXa and X 
to Xa
by thrombin, 
IXa, Xa, XIIa 
 
 
ND 
Factor VIII (VIII) →  
activated factor VIIIa 
(VIIIa) 
ceruloplasmin-
like binding 
protein 
cofactor for IXa in 
conversion of X to Xa, 
receptor for IXa and X, not 
enzymatically active 
 
by thrombin 
 
 
increase 
Factor IX (IX) →  
activated factor IXa 
(IXa) 
serine protease 
(endopeptidase)
the enzyme component of 
the intrinsic tenase, 
activates X to Xa 
by XIa or 
TF-VIIa/PL-
Ca2+ 
 
ND 
Factor X (X) →  
activated factor Xa 
serine protease 
(endopeptidase)
the enzyme component of 
the prothrombinase is 
by IXa-
VIIIa/PL-Ca2+,
 
ND 
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Precursor conversion HSPP 
identification 
The basic 
function in hemostasis 
Proteolytic 
activation 
Expression 
during the 
acute-phase 
response 
(Xa) responsible for rapid 
thrombin activation 
TF-VIIa/PL-
Ca2+ 
Factor XI (X) → 
activated factor 
XIa(XIa) 
serine protease 
(endopeptidase)
the conversion of IX to IXa 
within the intrinsic 
pathway 
by surface 
bound ǂ-XIIa 
 
ND 
Factor XII (XII) →  
activated factor XII  
(ǂ-XIIa)  
serine protease 
(endopeptidase)
initiation of the intrinsic 
coagulation pathway via 
conversion XI to XIa 
 
by kallikrein 
 
 
decrease 
Factor ǂ-XIIa (ǂ-XIIa) 
→ factor ǃ-XIIa 
(ǃ-XIIa) 
serine protease 
(endopeptidase)
solution phase activation 
of kallikrein, factor VII 
and the complement 
cascade 
 
by kallikrein 
 
 
decrease 
Factor XIII (XIII) →  
activated factor XIIIa 
(XIIIa) 
transglutami-
nase 
(transpeptidase)
stabilization of the fibrin 
clot via cross linking the ǂ 
and Ǆ-chains of Fn, ǂ2-PI, 
V, vWF  
 
by thrombin 
 
ND 
Anticoagulants  
Tissue factor pathway 
inhibitor (TFPI) 
Kunitz-type 
protease 
inhibitor 
reverse inhibition of Xa 
and IIa, then TF-VIIa 
independently from Ca2+ 
 
- 
 
 
decrease 
Antithrombin  
(AT) 
serpin Inhibition of VIIa, IXa, Xa 
and XIa, kallikrein, 
plasmin, IIa 
 
- 
 
decrease 
Protein C (PC)→ 
Activated protein C 
(APC) 
trypsin-like 
serine protease 
(endopeptidase)
inactivation of Va and 
VIIIa, that inhibits the 
prothrombinase and 
tenase and, finally, IIa 
by ǂ-throm-
bin/throm-
bomodulin, 
by Xa or IIa 
without Ca2+ 
no change or 
decrease 
Protein S (PS) binding protein as cofactor for APC - increase 
Fibrinolytic proteins  
Tissue-type 
plasminogen activator,
single chain form (sc-
tPA) → active two-
chain form (tc-tPA) 
serine protease 
(endopeptidase)
the main endothelium- 
derived activator of the 
fibrinolytic system, 
converts Pg to Pm 
 
by plasmin 
 
decrease 
or 
weak increase 
Glu-plasminogen 
(Glu-Pg) → 
plasmin (Pm) 
serine protease 
(endopeptidase)
responsible for the fibrin 
clot digestion 
by t-PA, u-PA, 
elastase, XIIa 
increase, 
2-3- fold 
Urokinase-type 
plasminogen activator,
single chain (sc-uPA) 
serine protease 
(endopeptidase)
activator of the Pg 
conversion to Pm 
 
- 
 
increase 
Proteinase inhibitors  
ǂ1-Antitrypsin or 
alpha 1-proteinase 
serpin protects tissues from 
proteolytic enzymes, 
 
- 
 
increase 
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Precursor conversion HSPP 
identification 
The basic 
function in hemostasis 
Proteolytic 
activation 
Expression 
during the 
acute-phase 
response 
inhibitor (ǂ l -PI) inhibits IIa and APC  
ǂ2-macroglobulin  
(ǂ2-M) 
broad-range 
protease 
inhibitor 
inhibits IIa, APC Pm, 
kallikrein, a remover of 
plasma enzymes 
 
- 
 
increase, 
about 100-fold 
ǂ2-antiplasmin (ǂ2 –
plasmin inhibitor) 
 (ǂ2 -PI) 
serpin inhibitor of Pm, forms 
covalent complexes 
interfered with the 
binding of Pg(Pm) to Fn 
 
- 
 
ND 
Thrombin activable 
fibrinolytic inhibitor 
(TAFI) → activated 
form (TAFIa) 
carboxypepti-
dase 
inhibitor of fibrinolysis, 
removes Pg-binding sites 
on Fn 
by thrombin, 
plasmin, 
trypsin 
 
 
ND 
Plasminogen activator 
inhibitor of type 1  
(PAI-1)  
serpin the major inhibitor of tPA 
that regulates the 
fibrinolysis by attenuation 
of Pm production 
 
- 
 
 
increase 
Plasminogen activator 
inhibitor of type2 
(PAI-2) 
serpin inhibitor of urokinase as 
well as tPA 
 
- 
 
ND 
Plasminogen activator 
inhibitor of type3 
(PAI-3 or PCI)  
serpin the major inhibitor of APC 
as well as tPA and 
urokinase 
 
- 
 
ND 
Table 1. The main characteristics of hemostatic soluble plasma proteins (HSPPs) 
Physiological anticoagulants are also available to suppress appropriate clotting factors. 
Some of the clotting factors (like thrombin or factor V) can promote both coagulation and 
anticoagulation; thus, these factors are called Janus-faced proteins.  
A hemostatic response to the activating signal is manifested by a series of transformations of 
proenzymes to activated enzymes in a cascade-like manner. The formation of thrombin at 
the final stage of the coagulation cascade is aimed at conversion of soluble fibrinogen into 
insoluble fibrin, the non-cellular matrix of blood thrombus. The thrombus formation is 
considerably accelerated due to accumulation of tissue factor (TF) at the sites of vascular 
endothelial damage. Tissue factor, a membrane-bound glycoprotein, is considered the 
common physiologic trigger of both hemostasis and inflammation pathways. Under normal 
conditions, none cells, which contact with the bloodstream, express TF. An injury, as the 
initial triggering signal, starts up the TF expression and the externalization at the surface 
ofinflammatory cells (primarily, monocytes) and vascular wall cells (endothelial or smooth 
muscle cells). Immediately upon exposure to the bloodstream, TF contacts with activated 
coagulation factor VIIa (VIIa), whose trace amounts (about 1 % of total inactive enzyme 
precursor, coagulation factor VII) are conventionally present in circulation. The formation of 
macromolecular complex TF-VIIa is a crucial event that initiates the first stage of the 
coagulation process, initiation phase. Alongside with that TF initiates local inflammatory 
reaction. 
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2.1 Initiation phase of the coagulation process 
Tissue factor-VIIa complexes, newly appeared on the boundary between blood flow and the 
vessel wall, begin to bind plasma-derived coagulation factor VII to produce additionally 
factor VIIa. Thus, TF acts as a cofactor in the factor VII/VIIa autoactivation process (Fig. 2). 
Membrane-bound TF/VIIa complexes also interact with small amounts of coagulation factor 
X (X) and coagulation factor IX (IX). Activated factors X (Xa) and IX (IXa) start up 
prothrombin (coagulation factor II) conversion to thrombin (IIa). This first cycle of restricted 
thrombin production is limited by two plasma-derived inhibitors, tissue factor pathway 
inhibitor (TFPI) and antithrombin (AT). The former one neutralizes factor Xa when forms a 
quaternary structure with TF-VIIa-Xa. As well, AT upon binding to heparan 
sulphate/heparin, rapidly inactivates free factors Xa, IXa, and thrombin, initially 
accumulated at the site of vascular injury. So, TF-VIIa itself is incapable to generate 
substantial amounts of thrombin during the initiation phase. However, the TF-dependent 
cycle of thrombin production can overcome inhibition by TFPI and AT, when TF is 
maintained at a sufficiently high level (Tanaka et al., 2009). Blood-borne forms of TF (soluble 
sTF or TF-positive microparticles) shed from disrupted cell membranes of different origin 
presumably can be an additional driver of the increased TF-initiated thrombin production 
(Sommeijer et al., 2006). Apparently, cell-exposed and blood-borne TF can promote 
transduction of inflammatory signals via cellular protease-activated receptors (PARs). For 
example, sTF-mediated inflammation in animal models might develop via platelet PAR-4 
signalling, while TF-proteases complexes (TF-VIIa and TF-VIIa-Xa ) induce the activity of 
signalling pathways in vascular cells via PAR-1 and PAR-2 (Busso et al., 2008; Rao & 
Pendurthi, 2005; Riewald & Ruf, 2001). Being a mediator of both inflammatory and 
hemostatic pathways, TF integrates different extra cellular signals and cellular responses, 
thus participating in the development of a host acute-phase response (Fig. 2). As an 
extremely potent triggering molecule, TF is capable of translating injury signals into 
activation of the coagulation cascade, sustaining thrombin initiation, and promoting its 
propagation. 
2.2 Propagation phase of the coagulation process 
Trace amounts of thrombin promote formation of a IXa-VIIIa-Ca2+-phospholipid assembly 
(tenase complex) or a Xa-Va-Ca2+-phospholipid assembly (prothrombinase complex) via 
feedback activation of non-enzymatic cofactors VIII (VIIIa) and V (Va) after their binding to 
negatively charged phospholipids (phosphatidylinositol and phosphatidylserine) on the 
surface of activated platelets in the presence of calcium ions. Thrombin also activates factor 
XI (XIa), which additionally stimulates the tenase complex. Tenase-produced 
prothrombinase complexes lead to the explosive generation of thrombin, which ultimately 
leads to generation of a fibrin clot. During an episode of TF-initiated coagulation, tenase and 
prothrombinase complexes are generated in concentrations that might be sufficient to 
maintain the TF-independent procoagulant response as long, as the reactants are available. 
From this moment, normal coagulation may become fully independent of TF (Butenas et al., 
2009). The propagation phase can continue and prolong the acute-phase response, where 
driving of thrombin generation is a requisite for an adequate bleeding prevention via more 
fibrin deposition. By binding to PARs, thrombin activates platelets, endothelial cells, and 
immune cells. As a result, cytokines and chemokines are additionally expressed, as well as 
certain HSPP secretion is intensified, leukocyte and platelet recruitment to inflammatory foci 
increases, and fibrin deposition is accumulated. These events considerably enhance local  
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Fig. 2. Schematic representation of the regulatory crosstalk between hemostasis and 
inflammation in response to exposed TF (coagulation factors and cytokines are all present in 
circulating plasma whereas TF is the only cell surface glycoprotein shown here). The 
interconnection of coagulation and inflammation pathways is an essential prerequisite for 
host homeostasis restitution after injury. Coagulation factors (as shown here with pink 
circles) and inflammatory mediators (blue circles) promote both coagulation and 
inflammation through complex and reciprocal interactions, thereby sustaining the acute 
phase response. At least, two clotting factors, factor VIIa and thrombin, contribute in pro-
inflammatory action of coagulation system through positive feed-back autoactivation 
mechanism (closed-loop arrows). Red curved arrow represents propagation phase of 
coagulation, blue curved arrow represents amplification of inflammation. In proportion to 
increasing levels of clotting and inflammatory APP, anticoagulation and anti-inflammation 
processes are activated. The limiting action of the anticoagulant and fibrinolytic systems on 
coagulation as well as anti-inflammatory mechanism of inflammation attenuation is 
depicted by brick-built barrier. Abbreviations: IIa, VIIa, IXa, Xa and XIa indicate activated 
coagulation factors; Fg, fibrinogen; Fn, fibrin; TF, tissue factor; PARs, protease-activated 
receptors; IL, interleukin; CRP, C-reactive protein; ICAM, intercellular adhesion molecule-1; 
PC/APC, protein C/activated protein C; AT, antithrombin; TFPI, tissue factor pathway 
inhibitor; IL-1Ra, interleukin-1 receptor antagonist; TGF-ß, transforming growth factor beta.  
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inflammation and coagulation. Furthermore, the formation of thrombi in the 
microvasculature provides a mechanical barrier that blocks spreading of 
inflammatory/coagulation mediators into the circulation. Such limited clotting restricts 
thrombus propagation and prevents from acute local inflammation turning into systemic 
complications. An anti-clotting molecular process induced by several physiological 
anticoagulants and fibrinolytic agents is designated for regulation of an adequate clot size 
and formation of an effective thrombus. Two hemostatic pathways, anticoagulation and 
fibrinolysis, both are responsible for coagulation termination (Fig. 2). 
2.3 Termination phase of the coagulation process 
After bleeding is arrested, and the injured vessel is repaired, coagulation attenuation begins to 
dominate over its propagation due to accumulation of inhibitors of blood clotting. Natural 
clotting inhibitors are orchestrated through successive induction of three major anticoagulant-
dependent pathways: tissue factor pathway inhibitor-, heparin/antithrombin- and the protein 
C-dependent pathways. A tissue factor pathway inhibitor (TFPI), as was mentioned above, is a 
most effective inhibitor of coagulation at the initiation phase. This inhibitor specifically blocks 
the TF-VIIa-Xa complex after trace factor Xa has been formed (Spronk et al., 2003). 
Antithrombin (AT) is a direct protease inhibitor, which attenuates accumulation of coagulation 
factors IXa, Xa, and IIa during the propagation phase. Heparin-like glycosaminoglycans 
accelerate the rate of inactivation of these clotting factors by AT. The protein C system 
provides multi-directional attenuation of thrombin procoagulant activity and this terminates 
coagulation. Thrombomodulin (TM), a endothelial cell membrane-associated protein, is 
capable of to tackling excessive thrombin, thus changing its specific enzyme activity. Within 
the thrombin-thrombomodulin complex, thrombin looses its affinity to fibrinogen or cellular 
PARs. Instead this, it possesses an ability to convert precursor protein C (PC) into an 
anticoagulant enzyme, activated protein C (APC). Activated protein C interrupts thrombin 
propagation via limited proteolysis of cofactors Va and VIIIa. Cofactor protein S and platelet 
membrane phospholipids provide manifold acceleration of the APC activity. Endothelial 
protein C receptors (EPCR) enhance the thrombin-thrombomodulin affinity to PC. In such a 
way the protein C system down-regulates the coagulation cascade to moderate the explosive 
trend of thrombin production. Its anticoagulant competence enhances, due to the modulation 
of the thrombin activity through two mechanisms, inhibition of prothrombin converting into 
thrombin and promotion of thrombin inversion from a procoagulant enzyme into an 
anticoagulant one. Inhibition of thrombin formation can also reduce thrombin’s pro-
inflammatory activities (Sarangi et al., 2010). 
In a complementary mode with respect to anticoagulation, the surplus clots are dissolved by 
proteases of the fibrinolytic system. Activation of intravascular fibrinolysis is controlled 
through enhancing synthesis and secretion of tissue plasminogen activator (tPA) by 
endothelial cells during fibrin clotting. Tissue plasminogen activator is released into the clot 
and binds in the clot volume with fibrin(ogen) and plasminogen (Pg). The formation of 
ternary Fn-tPA-Pg complex extremely effectively accelerates Pg converting into the serine 
protease plasmin (Pm). Plasmin cleaves fibrin into soluble fragments, the so called fibrin 
degradation products (FDPs). The rate and extent of local delivery of tPA during the clot 
formation is important for enhancing the process of fibrinolysis (Schrauwen et al., 1994). To 
avoid excessive clot digestion, which can affect bleeding, the activity of fibrinolytic system is 
down-regulated by numerous plasma- and cell-derived inhibitors (Meltzer et al., 2010). 
These are (i) plasminogen activator inhibitor of type 1 (PAI-1) that highly specifically 
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inactivates tPA, (ii) ǂ2-antiplasmin, primary Pm inhibitor that prevents Pm-dependent non-
specific proteolysis due to effective neutralization of Pm, and (iii) thrombin activable 
fibrinolytic inhibitor (TAFI) that down-regulates the cofactor activity of fibrin during 
activation of plasminogen and, thereby, suppresses fibrinolysis. 
The activities of both coagulation and fibrinolytic cascades are normally latent but have the 
potential to be accelerated in an extremely acute manner during inflammation. The 
coagulation and fibrinolysis pathways have to follow each other, retaining a delicate 
physiological balance preventing thrombosis and bleeding. Activation of the coagulation 
cascade leads to increases in the plasma levels of coagulation factors VIIa, Xa, and thrombin, 
which are pro-inflammatory factors contributing to the acute-phase response (Fig. 2). In 
addition, fibrin deposition and fibrin degradation products, FDPs, enhance inflammation. 
Coagulation factors elicit inflammation via affecting a number of blood/vascular cells 
through protease-activated receptor (PAR)-mediated pathways up-regulating the expression 
of numerous APPs (tumour necrosis factor-alpha, interleukins, adhesion molecules, and 
growth factors) (Chua, 2005). At least fibrin, thrombin, and coagulation factor Xa, all are 
important cell-signalling effector molecules that are responsible for receptor triggering. 
When PARs are activated constantly (e.g., under the action of repeated stimuli), the acute-
phase response can be inverted into a chronic one. Therefore, the inflammatory consequence 
caused by coagulation should be abolished within a necessary time intervals; otherwise it 
could be enormous. Resolution of the acute-phase response requires down-regulation of 
inflammatory/procoagulant APPs expression. In particular, IL-4, IL-10, TGF- ß are anti-
inflammatory agents that inhibit the production of numerous inflammatory cytokines, 
including TNF-ǂ, IL-1ß, IL-6, IL-8, and, finally, IL-10 itself (de Waal et al., 1991; Walley et al., 
1996). In fact, human blood monocytes are known to produce both pro- and anti-
inflammatory cytokines. During resolution, monocytes and macrophages considerably 
increase production of the latter above the former, thereby preventing prolongation or 
escalation of an early inflammatory response (Fig. 2). The concentration of cytokine-induced 
procoagulants is reciprocally decreased; thus, vascular homeostasis is restored. 
A failure of the control of these processes causes incorrect inflammation termination or even 
its propagation. Such an inconsistency leads to deregulation of hemostasis, which, in turn, 
might force the further leap of inflammatory responses. Under pathological conditions, 
cytokines are released by immune regulatory cells in sites of the local inflammatory 
response. This process may be acute but limited in time (reverting to the normal homeostatic 
state) or persistent (resulting in chronic activation of coagulation and fibrinolysis). Initially 
acting within the frame of  the adaptive defence system, inflammation and hemostasis might 
develop from a local response to a systemic host reaction. Escalation of inflammation can 
induce endothelial dysfunction subsequently activating the coagulation cascade, and vice 
versa — hypercoagulation follows amplification of inflammation (Levi et al., 2004)  
Under these conditions mutual activation of coagulation and fibrinolysis might follow to 
potentially exhausting consumptive coagulopathy and disseminated intravascular 
coagulation. A detrimental inflammatory response resulting from coupling of procoagulant 
and pro-inflammatory stimuli might cause thrombophilia, and, furthermore, provoke the 
thrombotic events. In such a way, inflammation/coagulation interaction drastically 
increases a risk of thrombus formation implicated in the pathogenesis of several diseases in 
humans. On the one hand, these are thrombophilias, atherosclerosis, and other cardio-
vascular pathologies, as well as intercurrent illnesses (like trauma and cancer) or surgery. 
On the other hand, these are acute/chronic inflammatory diseases, including sepsis, 
inflammatory bowel disease, and lung and heart inflammation (Fig. 3). 
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Fig. 3. A simplified hypothetic model of pathophysiological interactions between 
inflammatory and hemostatic APPs. Each spiral turn represents a potentially vicious cycle 
driven by excessive concentrations of some components (this is shown as arrows up) and/or 
insufficient concentrations of other components (as arrows down). Amplification of HSPP 
activation during an initiation phase is exerted through interaction with the components of 
the innate immune system, which, in turn, prolongs inflammation during the propagation 
phase. As a result, both processes, coagulation and inflammation, can come into 
perpetuation phase. These complex interactions can lead to life-threatening complications, 
such as thrombosis or sepsis. Refer to the text for discussion in detail.  
Abbreviations: IIa, VIIa, IXa, Xa, and XIa indicate activated coagulation factors; Va and VIIIa – non 
enzymatic cofactors; Fn, fibrin; TF, tissue factor; sTF, blood-borne (soluble) forms of tissue factor; PARs, 
protease-activated receptors; IL, interleukin; CRP, C-reactive protein; TNF−ǂ, tumour necrosis factor 
alpha; tPA, tissue activator of plasminogen; APC, activated protein C; AT, antithrombin; PAI-1, 
plasminogen activator inhibitor of type 1; TAFI, thrombin activable fibrinolytic inhibitor. 
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3. Pro-inflammatory environment sustains coagulation 
Recently, a clear association of high APP levels with a human procoagulant phenotype and 
impaired fibrinolysis were found in some studies. Indeed, a certain relationship is believed 
between the plasma levels of C-reactive protein (CRP) and some HSPPs. C-reactive protein 
is at present used as a sensitive biomarker of acute and chronic inflammation. This is the 
only APP that correctly displays the severity of vascular pathologies: from an endothelium-
derived focal inflammatory response to a hard coronary lesion (Calabrò et al., 2009; 
Willerson & Ridker, 2004). CRP levels are now detected using a high-sensitivity assay 
(hsCRP); these indices are found to be an accurate predictor of cardiovascular disease (CVD) 
(de Ferranti & Rifai, 2007).  
The procoagulant function of the C-reactive protein is still debated (MacCallum, 2005), but 
there is some evidence proving that CRP is associated with the metabolism of HSPP. In ex 
vivo experiments on cell systems, CRP was found to induce expression of inflammatory 
cytokines or TF in monocytes (Cermak et al., 1993), of thrombomodulin and von Willebrand 
factor (vWF) in human umbilical vein endothelial cells (HUVECs) (Blann & Lip, 2003), and 
of PAI-1 in human arterial endothelial cells (HAECs) (Chen et al., 2008; Devaraj et al., 2003). 
Close correlation of the CRP amount with increasing fibrinogen levels was found in patients 
with acute ischemic stroke (Tamam et al., 2005). The CRP expression reflects not only to be a 
predictor but rather an active mediator of atherothrombotic events, as was reported for in 
vivo CRP-dependent induction of TF in blood monocytes (Sardo et al., 2008). Increased levels 
of hsCRP are associated with such CVD, as severe unstable angina, myocardial infarction, 
stroke, and peripheral arterial disease (de Ferranti & Rifai, 2007). The causative role of CRP 
in thrombogenesis is at present believed doubtful, but its active participation is supported 
by some results described earlier. One of the small group evaluation reports revealed that 
activation of coagulation and fibrinolysis induced by recombinant CRP infusion provoked 
increases in the levels of prothrombin F1+2 and D-dimer, as well as in the vWF and PAI-1 
concentrations (Bisoendial et al., 2005). CRP also attenuated the fibrinolytic capacity, by 
inhibiting the tPA activity and stimulating PAI-1. An increased ECLT (euglobulin clot lysis 
time) and, hence, a decreased fibrinolytic capacity in the blood plasma obtained from 
volunteers with high CRP levels were found (Zouaoui Boudjeltia et al., 2004). These data 
confirm a conclusion on down-regulation of fibrinolysis during the enhanced inflammatory 
response indicated by CRP.  
The studies that elucidate the inhibitory role of cytokines in fibrinolysis are not limited to 
that of CRP. A multifunctional cytokine, IL-1, was shown to stimulate up-regulation of 
specific mRNA expression of urokinase-type plasminogen activator (u-PA) (Wojta et al., 
1994). IL-1 also increased accumulation of PAI-1 in cardiac microvascular endothelial cells 
(Okada et al., 1998) and also controlled expression of PAI-1 and u-PA in human astrocytes 
(Kasza et al., 2002). Production of PAI-1 protein in human adult cardiac myocytes was found 
to be increased up to two times by interleukin-1ǂ and tumour necrosis factor-ǂ (TNF-ǂ) and 
up to five times by transforming growth factor-ß (TGF- ß ) and oncostatin M. However, t-PA 
production in human cardiac myocytes did not change after cytokine treatment (Macfelda et 
al., 2002). By contrast, IL-1 and tissue necrosis factor alpha inhibited t-PA in HUVEC 
(Bevilacqua et al., 1986). 
During severe inflammation, the function of fibrinolysis can be impaired. The same is true 
with respect to anticoagulant pathways. It was recently documented that an increase in 
serum CRP level in dogs was accompanied by lowering of the AT concentration (Cheng et 
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al., 2009). Under inflammation conditions, the AT plasma level can decreased due to 
impaired synthesis (like other negative APPs) or due to protein degradation by elastase 
produced by activated neutrophils (Viles-Gonzalez et al., 2005). In addition, AT might be 
consumed proportionally to inhibition of the target proteases or removed from circulation 
after binding to fluid-phase complement attack complexes within the complement cascade 
(Esmon, 2005). Another natural anticoagulant, TFPI, seems to be incapable of regulating an 
enhanced thrombin amount during severe inflammation, since a low endogenous 
concentration of the anticoagulant does not increase (Bastarache et al., 2008). It would be 
noted that TFPI concentrations do not follow the development of disseminated intravascular 
coagulation and cannot prevent hypercoagulation (Wiinberg et al., 2008). TFPI is expressed 
primarily in the microvessels; thus, it might only nominally participate in hemostasis 
balancing in the larger vessels. Apparently, this pathway only slightly contributes to the 
coagulation/inflammation cross-over (DelGiudice & White, 2009). The PC anticoagulant 
system is more extensively present in the vascular network (Viles-Gonzalez et al., 2005). 
This system plays a pivotal role in hemostasis, shutting down coagulation and promoting 
fibrinolysis. These events might fail because of the presence of some vulnerable 
components. Down-regulation of membrane TM and EPCR by endotoxin, IL-1b, and TNF-ǂ 
has been noted elsewhere (Esmon, 2005). The disappearance of TM from the endothelial cell 
surface impairs the process of activation of protein C. Not only the amount of APC but also 
its anticoagulant activity might be decreased under pathological conditions. Protein S, when 
forming an inactive complex with complement protein C4b (C4BP), thereby looses its ability 
to promote APC (Dahlback, 1991). Additionally, soluble forms of TM and EPCR can appear 
during inflammation in the blood flow. They may bind APC without potentiation of its 
activity or, moreover, even might inhibit APC anticoagulant function. sEPCRs have been 
found to block binding of protein C and APC to phospholipids and to alter the active site of 
APC (Liaw et al., 2000). 
Tissue factor, in addition to its procoagulant function, has been recently identified as a key 
secondary inflammatory mediator that markedly accelerates the feedback intensification of 
coagulation and inflammation pathways. Its concentration in circulation dramatically 
increases when the endothelium is disrupted and the blood begins to contact with extra 
vascular cells. In addition, inflammatory mediators many times increase the tissue factor 
protein amount and activity through stimulation of expression of this protein and through 
increasing the number of TF-positive microparticles as a consequence of paracrine and 
autocrine activity of the inflammatory cells (Esmon, 2005). It should be noted that TNF-ǂ 
and IL-1ß are produced by lymphocytes and macrophages during vascular inflammation, 
and these events can also enhance the expression of the TF. The TF expression can be 
stimulated by several inflammatory mediators, namely TNF-ǂ, IL-1, IL-6, activated 
complement, and immune complexes (DelGiudice & White, 2009). Activated T cells increase 
both TF expression and activity via paracrine stimulation of endothelial cells (Monaco et al., 
2002). LPS-stimulated monocytes enhance intracellular transport of increased amounts of TF 
to the cell surface as well as the shedding of TF-containing microparticles (Egorina et al., 
2005). Subsequently, soluble TF indirectly promotes inflammation by stimulation of 
thrombin production and by involvement of platelets via thrombin-activated PAR-
dependent signalling. In PAR-4-deficient mice, recombinant sTF did not induce 
inflammation but was able to activate thrombin production, demonstrating, in such a way, 
the necessity of thrombin-sensitive platelets for sTF-mediated inflammation (Busso et al., 
2008). Activation of platelets leads to release, from their  ǂ-granules, of a cocktail of 
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chemokines and cytokines including IL-8, platelet factor–4 (PF4), and macrophage 
inflammatory protein–1a (MIP-1a) and to the expression of platelet surface adhesion 
molecules including P-selectin and CD40-ligand (CD40L). Platelet-derived CD40L is able to 
induce TF on the cell surface of endothelial cells and also of monocytes (Lindmark et al., 
2000). Apparently, interaction between TF and flowing blood prolongs activation of the 
coagulation cascade through additional thrombin generation, which, in turn, might 
potentiate the formation of a platelet-rich thrombus. As was found recently, the 
inflammatory response involves activation not only of blood-borne cells (leukocytes and 
platelets), but also of the cells derived from the vascular wall (endothelial and smooth 
muscle cells, etc.). Binary TF-VIIa and ternary TF-VIIa-Xa complexes can also modulate 
inflammation via protease-activated receptor 2 (PAR 2) cleaving (Ahamed et al., 2006). Some 
vascular-bed specificities influence the TF-dependent mechanism of modulation of the acute 
response. In particular, vessel wall- derived TF forces mainly arterial thrombogenesis, since 
instable or ruptured atherosclerotic plaques are characterized by a high concentration of TF 
in both cellular and acellular regions. At the same time, soluble TF contributes mainly to 
venous thrombosis and microvascular thrombosis (Owens & Mackman, 2010). Nevertheless, 
circulating TF was found to be associated with the increased blood thrombogenicity in 
patients with unstable angina and chronic coronary artery disease (Corti et al., 2003). TF 
causes progression of coagulation within initial stages of disseminated intravascular 
coagulation (DIC) (Wiinberg et al., 2008). In animal models, TF was shown to participate in 
generalization of deep vein thrombosis (DVT) (Himber et al., 2003). Some reports indicate 
that myocardial inflammation and cardiomyocytes injuring enhance expression of TF, 
thereby increasing local formation of thrombin (Erlich et al., 2000; Luther et al., 2000).  
Coagulation factor Xa was found to increase induction of endothelial TF and E-selectin by 
all the pro-inflammatory cytokines (e.g. TNF, IL-1ß, and CD40L). TF, in turn, initiates a new 
wave of factor Xa production after the formation of the TF-VIIa complex and activation of 
zymogens of factors IX and X. Binding of TF-VIIa to PAR-2 also results in up-regulation of 
the inflammatory responses in macrophages and neutrophils (Cunningham et al., 1999). A 
synergistic pattern of activity of factor Xa and inflammatory cytokines, resulting in both re-
activation of coagulation cascade and augmentation of inflammatory mediators, is a good 
illustration of the apparent positive feedback mechanism, by which enhanced coagulation 
maintains pro-inflammatory environment and vice versa (Hezi-Yamit et al., 2005) . 
4. Hypercoagulation and impaired fibrinolysis perpetuate inflammation 
The above-mentioned facts proved the capacity of the inflammatory factors to regulate 
coagulation and fibrinolysis. A converse molecular mechanism, by which hemostasis 
stimulates inflammation is at present less obvious but undergoes increasing investigations. 
Fibrinogen, the precursor of fibrin, is considered a rapid and sensitive marker of both 
coagulation and the acute-phase response, while its synthesis is enhanced during early 
inflammatory reactions. Fibrinogen contributes to coagulation being a terminal substrate in 
plasma clotting, which is cleaved specifically by thrombin. By splitting fibrinopeptide A and 
fibrinopeptide B from fibrinogen thrombin forms fibrin-monomers are spontaneously 
polymerized producing fibrin. Fibrin, in turn, provides plasma clotting, platelet aggregation 
and wound healing or thrombus formation. In addition, fibrin(ogen) participates in 
activation of vascular cells and regulation of the inflammatory response. Pro-inflammatory 
effects of fibrin(ogen) manifest itself after the abnormal fibrin deposition; this affects the 
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vascular bed and enhances primarily local and, then, systemic inflammation through 
expression of the pro-inflammatory mediators. In fact, fibrin(ogen) increases the mRNA 
levels and induces synthesis of inflammatory cytokines IL-6 and TNF-alpha in human 
peripheral blood mononuclear cells (PBMCs) (Jensen et al., 2007), of IL-8 in HUVEC (Qi et 
al., 1997), and of transcription factor NF-kB in mononuclear phagocytes (Sitrin et al., 1998). 
Fg can manifest a pro-inflammatory action independently of its clotting function due to the 
existence of a high-affinity integrin binding site or multiple low-affinity binding sites, which 
interact with inflammatory competent cells. In particular, induction of cytokines IL-1ǃ, IL-6, 
TNF-ǂ has been found to be associated with fibrin binding to integrin receptors Mac-1 
(CD11b/CD18) in monocytes (Trezzini et al., 1991). Cytokine secretion is suggested to be 
directly triggered by the process of Fg polymerization to Fn. The activity of thrombin that 
increases in Fg-deficient mice after LPS administration does not correlate with the levels of 
inflammatory mediators produced by bone marrow-derived macrophages and duration of 
their action. Both thrombin and Fg acting separately or in combination exert no effect on the 
cytokine production. It was concluded that up-regulation of secretion results in 
conformation changes of the Fg molecular structure during its conversion into Fn (Cruz-
Topete et al., 2006). Some recently obtained data supported this conclusion. Molecular 
determinants of fibrin(ogen)-mediated pro-inflammatory activity were found to be localized 
in a Ǆ-chain. These determinants can enhance the inflammatory cell recruitment and 
activation via interaction with integrin receptors Mac-1. Several specific sequences (all are 
attributed to the fibrinogen Ǆ-chain) were found to participate in the interaction of 
fibrinogen with leucocytes. There are Ǆ190-202, Ǆ377-395, and Ǆ383-395 sequences (the latter 
is localized within the Ǆ-chain of the D nodule), which are capable of affecting leukocyte 
adhesion, their migration, or cytokine expression (Jennewein et al., 2011). In addition to 
Mac-1, leukocyte integrin receptors ǂMß2 (but not platelet receptors ǂIIbß3) may be involved 
in the progression of inflammatory disease (Flick et al., 2004; Flick et al., 2007). The core 
recognition motif, Ǆ-chain residues 383–395, was suggested to determine the affinity of Fg 
and Fn to ǂMß2. Obviously, soluble Fg has cryptic ǂMß2 binding sites, which are inaccessible 
for integrin ǂMß2 binding. Structural conformation changes during Fg immobilization or 
conversion of the latter into Fn permit Fg/Fn binding to integrin and provide local 
leukocyte activation. Being non-diffusible component fibrin deposition attaches to site of 
injury, marking spatial and temporal coverage for inflammatory cell targeting. Indeed, one 
might speculate that fibrin-mediated activation of ǂMß2 in macrophages and neutrophils 
represents a possible mechanism of the inflammatory response amplification during 
hypercoagulation. As a result, NF-kB-dependent intracellular signaling, which is triggered 
by fibrin interaction with ǂMß2, leads to a vicious cycle of cell recruitment, adhesion, 
degranulation, generalization of oxidative responses and release of inflammatory mediators 
(Flick et al., 2004; Flick et al., 2007). 
The involvement of fibrinogen in coagulation, as well as that of fibrin in the fibrinolytic 
process, is accompanied by generation of the various fibrin(ogen) degradation products, 
FDPs. These small and large fragments can exert an independent regulatory effect on the 
inflammatory process. In particular, fibrinopeptides A and B, the products of Fg conversion 
into Fn, are suggested to show a pro-inflammatory action on leucocytes functioning as 
chemoattractants. In contrast, the peptide Bǃ15-42 which is generated by plasmin cleavage 
of fibrin, can mediate powerful anti-inflammatory effects. FDPs, which are formed after 
Fg(Fn) digestion by plasmin, also seem to modulate inflammation (Jennewein et al., 2011). 
Fg, Fn and FDPs were shown to induce intensification of CRP production in vascular 
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smooth muscle cells. Herein, FDPs have the most prominent pro-inflammatory potency, as 
compared to that of fibrin(ogen) (Guo et al., 2009).  
It is interesting that plasmin(ogen) also generates degradation products during activation of 
fibrinolysis. These are either the first three, or the first four kringle domains (K1-3, K1-4) or 
only kringle domain 5 (K5). Angiostatin, a proteolytic fragment that contains K1-4, acts as a 
powerful anti-inflammatory modulator. In particular, angiostatin demonstrated a lowering 
adhesiveness of leukocytes to extracellular matrix proteins and the endothelium. Interaction 
of the angiostatin kringle domain K4 with integrin receptor Mac-1 down-regulates 
transcriptional factor NF-kB, whereby attenuates NF-kB-related expression of neutrophil-
derived tissue factor (Chavakis et al., 2005). The kringle domain K5 has been found to 
restrict the neutrophil chemotactic activity (Perri et al., 2007). Obviously, impaired 
fibrinolysis looses this anti-inflammatory action. 
The formation of fibrin deposition is a direct consequence of increased thrombin production. 
A pro-inflammatory action of thrombin is realized by two interdependent ways: (i) by direct 
promotion of hypercoagulation accompanied by the pro-inflammatory effects described 
above; (ii) by stimulation of vascular and blood-borne cells and their further involvement in 
the inflammatory response. Being a powerful signal molecule, thrombin interacts 
specifically with PAR-1, PAR-2, or PAR-3 and activates the signaling pathways in 
endothelial cells, platelets, mononuclear cells, and fibroblasts. Thrombin-induced 
intracellular pathways up-regulate the expression of several cytokines and growth factors, 
as well as the secretion of intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1) (Levi & Poll, 2008). Thrombin is a key protease-agonist, 
which controls the platelet involvement in the formation of thrombi by stimulation of 
platelet aggregation, granule secretion, and additional recruitment in the inflammatory 
process. In an in vitro endothelial-cell-monolayer model, thrombin was shown to affect PAR-
1-mediated signalling in a concentration-dependent manner. Low thrombin concentrations 
(20–40 pM) results in endothelial barrier protection, whereas high thrombin concentrations 
(> 80 pM) lead to disruption of this barrier (Feistritzer & Riewald, 2005). When activated 
protein C occupies PAR-1, thrombin can realise disruptive effects through activation of 
PAR-4; this effect requires a higher concentration of thrombin (Bae et al., 2007). Upon 
binding to thrombomodulin, thrombin inverts its coagulant and inflammatory functions 
into anticoagulant and anti-inflammatory ones. TM competes effectively with procoagulant 
substrates (fibrinogen, V, VIII, and PARs) for the same exosite-1 of thrombin but inhibits 
activation of the coagulation cascades. Moreover, a thrombin-TM complexation down-
regulates inflammation/coagulation-pathways via a feedback inhibition mechanism, while, 
at the same time, it initializes protein C-dependent anticoagulant pathway via PC activation 
(Bae et al., 2007). APC, in addition to its anticoagulant function, acts as a pleiotropic agent 
with anti-inflammatory, profibrinolytic, and cytoprotective effects. After its activation, APC 
dissociates from the thrombin-TM complex and comes into plasma, where it acts as 
anticoagulant and profibrinolytic agent, or binds to cell membrane EPCR and regulates 
intracellular inflammatory pathways. APC is now considered as a signaling molecule that 
possesses an ability to selectively regulate cytokine production during the inflammatory 
response. On the one hand, APC down-regulates the production of such pro-inflammatory 
cytokines, as TNF-ǂ, IL-1ß, IL-6, and IL-8 in monocytes (Stephenson et al., 2006). On the 
other hand, APC up-regulates anti-inflammatory IL-10 that can reduce the protein 
concentration and activity of TF, as it was found after treatment of LPS-stimulated 
monocytes with recombinant APC, rAPC (Toltl et al., 2008). NF-kB-mediated signal 
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transduction events are modulated directly by APC interaction with EPCR on the plasma 
membrane of endothelial cells and mononuclears. APC-EPCR inhibits NF-kB nuclear 
translocation, which then results in inhibition of downstream NF-kB-regulated genes, e.g., 
ICAM-1, VCAM-1, and E-selectin in endothelial cells or TF in mononuclear cells (Joyce et al., 
2001; White et al., 2000). APC has recently been reported to impair TNF signaling in vascular 
endothelial cells by preclusion of phosphorylation of NF-κB p65 and, thereby, by 
attenuating expression of cell adhesion molecules (including VCAM-1) (Guitton et al., 2011). 
At the same time, APC does not affect neutrophil respiratory bursts, phagocytic activity, and 
expression of monocyte adhesion molecules (Stephenson et al., 2006). In fact, APC does not 
seem to suppress the innate defensive mechanisms. As a consequence, the action of 
inflammatory cytokines and oxidative agents sharply reduce the efficiency of TM in PC 
activation and promote pro-inflammatory efficiency of thrombin. 
5. Phenotypic variability of hemostasis during acute and chronic 
inflammation 
Abnormal exposure of the procoagulant and pro-inflammatory agents contributes to 
sustaining of both local and systemic procoagulant/inflammatory potentials. Prolonged 
activation of inflammatory cells promotes the production of large amounts of inflammatory 
mediators by downstream-cells affecting not only via an autocrine mechanism, but also in a 
paracrine manner. The duration and amplitude of a cytokine-mediated systemic 
inflammation signal, upon reaching the liver, determine the probable pattern of HSPPs 
additionally produced during the acute inflammatory response. The HSPP level is known to 
be up-regulated by various pro-inflammatory cytokines similarly to other acute phase 
proteins, i.e., at the transcriptional and post-transcriptional levels. Genetic factors per se may 
contribute in different manners to a total variability of the HSPP systemic levels: cover about 
50% variation in the fibrinogen level or 30% in factor VII plasma level, but exert a negligible 
effect on the plasma level of t-PA (neither that of antigen nor of its activity) (Voetsch & 
Loscalzo, 2004). Activated protein C, that breaks thrombus generation through regulation of 
both coagulation and fibrinolysis apparently is not  additionally expressed during the acute-
host response. There is some evidence that cytokine-dependent down-regulation of protein 
C synthesis occurs (Yamamoto et al., 1999); this allows one to classify this agent rather as a 
negative acute-phase protein. In case, lowering of the plasma protein C level is observed in 
some diseases, which are attended with inflammation (Danese et al., 2010). Another fact, 
which is a stronger proof, is that cytokines decrease the capacity of the endothelium to 
activate protein C precursor in activated protein C because they are able to down-regulate 
the amount of endothelial membrane-bound thrombomodulin (Esmon, 2004). Alternatively, 
some authors hypothesize that plasma pool of precursor PC can rapidly decline because of 
enhanced APC consumption after counteracting with plasma inhibitors (Danese et al., 2010; 
Patalakh et al., 2009). It is obvious, that in pathological states, the relative proportions of 
HSPPs significantly vary depending on either driving or suppression of their production by 
inflammation. Changes in the plasma protein ratio can lead to disproportion between 
procoagulant and anticoagulant patterns under different pathophysiological conditions. 
Activated proteases are rapidly cleared from circulation and this determines only a crude 
assessment of their production. That is why their plasma levels do not always respond “in 
unison” upon systemic inflammation. 
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5.1 Transcriptional regulation of HSPP production during inflammation  
Unlike CRP (type-1 acute phase protein) up-regulated by synergistic action of IL-6 and IL-
1beta, most hemostatic proteases (type-2 acute phase proteins) require IL-6 alone for 
maximal induction of their synthesis (Trautwein et al., 1994). IL-6 is a key effector that 
effectively promotes the coagulation pathway, not only by up-regulation of expression of 
some procoagulant factors (such as TF, fibrinogen, and factor VIII) but also by down-
regulation of synthesis of some anticoagulants (such as antithrombin and protein S) (Hou et 
al., 2008). Cytokine IL-6 is suggested to act as a common inductor for several vascular acute-
phase proteins (CRP, ǂ- and ǃ- chains of Fg, Pg, ǂ2-macroglobulin, and PAI-1). Under 
transcriptional control by the cytokine IL-6, their circulating levels increase via cooperative 
up-regulation of the corresponding gene promoter activity. The congruence of the HSPP 
gene responses to IL-6 is provided by an IL-6- responsive element (IL6-RE) that is required 
for maximal stimulation of the promoter activity by IL-6 (Bannach et al., 2004). Interestingly, 
IL-6-REs were identified in human CRP and ǂ2-macroglobulin genes, as well as in two genes 
responsible for synthesis of fibrinogen ǂ- and ß-chains. The same IL-6-REs is located in the 
region identified as a cytokine-response region of murine Pg and human PAI-1(Bannach et 
al., 2004; Loppnow & Libby, 1990). More than one IL-6-RE can exist in the promoter region 
required for the full responsiveness to IL- 6. Two macroglobulin promoters, e.g., have two 
functionally cooperated REs, which provide the full IL-6 response of the gene (Trautwein et 
al., 1994). It was assumed that any small differences in the amount or sequence homology of 
IL-6-REs in the HSPP genes can vary their inducibility by IL-6 (Hattory et al., 1990). 
Likewise, distinct transcription factors help to transduce the inflammation signal from 
cytokine to IL-6-RE in a cell- and/or tissue-specific manner. Such mechanisms might allow 
differential regulation of HSPPs gene expression induced by IL-6. IL-6-dependent 
regulatory machine is a good example for demonstration how the overall expression of a 
single plasma protease gene can be controlled by the inflammatory signal that begins in the 
extracellular milieu and terminates at separate sites on the promoter region of the gene. 
Not only IL-6, but a number of cytokines, alone or in a combination, may also influence 
HSPP synthesis. TNF-ǂ and other inflammatory agents are known to markedly suppress 
fibrinolysis, mainly via stimulation of PAI-1 and down-regulation of t-PA expression. The 
transcriptional and post-transcriptional regulation of the fibrinolytic system by 
inflammatory signals was recently reviewed in detail (Medcalf, 2007). Simultaneously acting 
cytokines can exert additive, inhibitory, or synergistic effects on the HSPP production. TNF-
ǂ and IL-1 provide mutual down-regulation of the mRNA for murine protein C. These 
cytokines are able to control gene expression independently or in combination with IL-6 
(Yamamoto et al., 1999), whereas IL-6-mediated induction of Fg synthesis was partially 
inhibited by IL-1 or TNF-ǂ (Mackiewicz et al., 1991). Various environmental factors and 
individual features of the patient (including age, body mass index, levels of plasma 
triglycerides and atherosclerotic transformation of the vessel wall) influence the cytokine-
regulated levels of HSPP. For instance, shear stress can up-regulate cytokine-induced 
expression of t-PA, TGF-ß1, and ICAM-I genes at the transcriptional level (Kawai et al., 
1996). These additional influences modify local or systemic inflammatory responses 
depending on the host phenotype (Lowry, 2009). 
5.2 Alterations of the HSPP plasma levels caused by post-transcriptional and post-
translational events  
Marked alterations in the plasma HSPP levels following an acute-phase stimulus are 
determined not only by transcriptional regulation but also by post-transcriptional and post-
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translational mechanisms. The latter were found for such classic APPs, as serum amyloid A 
(SAA), complement factors B, and C3 (Jiang et al., 1995). It was reported that the ǂ2-
macroglobulin gene transcription rate might increase (up to nine-fold) during the acute 
inflammatory response, while its protein plasma concentrations can rise much more 
significantly (to 100-fold) (Hattory et al., 1990). The other study demonstrated that aortic 
endothelial cells decreased production and secretion of t-PA after incubation with CRP 
without any alteration of the tPA mRNA level, thus underlying a suggestion that CRP-
mediated tPA inhibition is a posttranscriptional event (Singh et al., 2005). In contrast, post-
transcriptional regulation should not play a substantial role in monocyte-derived 
production of fibrinogen ǂ-chain or ǂ-1 protease inhibitor (ǂ -PI) proteins (Jiang et al., 1995).  
Despite the HSPPs are largely regulated by transcriptional control, they still strongly require 
the post-transcriptional regulation (including co-translational and post-translational 
modification) to confer their optimal functionality. They should form the disulfide bonds to 
get native conformation as well as should be carboxylated, hydroxylated, phosphorylated, 
sulfated or glycosylated to achieve a specific function. In particular, the main coagulation 
factors II, VII, IX, X and protein C (all are the vitamin K-dependent proteins) are processed 
through further post-translational modification to become biologically active. Prior to 
secretion into the blood they should be modified by a vitamin K-dependent gamma-
glutamyl carboxylase, getting in such a way, an amount of negatively charged Ǆ-
carboxyglutamic acid (Gla) residues. Gla-residues have a chelating activity oriented to Ca2+-
cations (Table 2). They are orchestrated in the "Gla domain" to participate in the Ca2+-
dependent binding of parent protein to cell membrane or macromolecular complexes.  
Similarly to most secretory proteins, HSPPs are enriched by disulfide bonds (Table 2). Before 
secretion, they undergo oxidative maturation that leads to binding of the appropriate pairs 
of cystein residues. The disulfide bonds are formed in the rough endoplasmic reticulum, 
since this process requires an oxidative environment. These functional groups are well-
known as playing an important role in protein folding (by stabilizing the tertiary and 
quaternary structure). Furthermore, disulfide bonds can be responsible for intra- and 
intermolecular reorganization or even proteins aggregation. In the few last years, a number 
of studies on functional disulfides have highlighted their two important functions, namely 
catalytic and allosteric (Chen & Hogg, 2006; Manukyan et al., 2008; Popescu et al., 2010). 
In addition to carboxylation and formation of disulfide bonds, a series of post-translational 
modifications occurs to attach N- or O-linked glycans to secreted proteins (Table 2). Several 
N-linked glycosylation sites are well-known to be an attributive feature of HSPPs, which are 
glycoproteins. N-glycosylation has been recently discovered to be a crucial event in the 
regulation of the glycoprotein structure and function. Via promotion or inhibition of intra- 
and intermolecular binding, glycans can regulate protein folding, cell adhesion and 
aggregation. Glycosylation can also modulate the activity of plasma membrane receptors at 
the surface of the vascular endothelial cells, platelets, and leukocytes influencing in such a way 
intracellular signal transduction systems, which are responsible for homeostasis in circulation 
(Skropeta, 2009). Probably, a degree of initial core glycosylation might affect the efficiency of 
protein’s Ǆ–carboxylation in endoplasmic reticulum  before secretion (McClure et al., 1992). 
There are available data, suggesting that glycosylation is higher in proteins synthesized 
during the acute-phase responses. In vitro studies with isolated hepatocytes and hepatoma 
cell lines proved that inflammatory cytokines regulate changes in glycosylation 
independently of the rate of synthesis of the APP (Van Dijk & Mackiewicz, 1995). Variations 
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Protein 
Percent 
carbo-
hydrate
(w/w) 
number of modified residue 
 
Glycosylation
 
 
Disulfide bond
Hydroxylation, 
phosphorylation or
sulfation 
 
Carboxylation 
fII  3 N-linked 
10 
(+2 predicted)
none 10 Gla residues 
fV ~25% 
5 N-linked 
(+21 predicted)
6 
(+1 predicted)
1 phosphothreonine
1 phosphoserine 
7 sulfotyrosine 
 
none 
fVII 13% 
2 O-linked 
2 N-linked 
12 
one ǃ-
hydroxyaspartate 
10 Gla residues 
fVIII  
1 N-linked 
(+21predicted)
7 
(+1 predicted)
6 sulfotyrosine none 
fIX 
 
17% 
 
4 O-linked 
2 N-linked 
11 
one ǃ-
hydroxyaspartate 
2 phosphoserine 
1 sulfotyrosine 
 
12 Gla residues 
fX 15 % 
2 O-linked 
2 N-linked 
12 
one ǃ-
hydroxyaspartate 
11 Gla residues 
fXI 5% 5 N-linked 18 2 phosphorilated none 
fXII 17% 
7 O-linked 
2 N-linked 
20 none none 
Glu-Pg ~2% 
2 O-linked 
1 N-linked 
24 1 phosphoserine none 
tPA  
1 O-linked 
3 N-linked 
17 none none 
TFPI  
2 N-linked 
3 O-linked 
9 none none 
AT 9% 4 N-linked 3 1 phosphoserine none 
PC 23 % 4 N-linked 12 
one ǃ-
hydroxyaspartate 
9 Gla residues 
ǂ2 -PI 14% 4 N-linked 1 1 sulfotyrosine none 
PAI-1  
2 N-linked 
(+1 predicted)
none none none 
TAFI  5 N-linked 3 none none 
(Data based on Protein Knowledgebase UniProtKB) 
Table 2. Post-translational modifications of the major hemostasis soluble plasma proteins 
in different glycoforms of APP in circulation most likely result from alterations in 
oligosaccharide branching, increased sialylation, and decreased galactosylation (Gabay & 
Kushner, 1999). The replacement of individual N-glycans by other ones exerts very specific 
and diverse effects on the protein structure and/or function. Human hemostatic proteins, 
coagulation factor IX and protein C, which both are the vitamin K-dependent proteins 
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synthesized and secreted by hepatocytes, vary extensively in their glycosylation levels. 
Coagulant factor IX has two N-glycosylation sites and is characterised by significantly more 
heterogeneity of N-glycan structures than anticoagulant protein C. PC has four N-
glycosylation sites, Q97, Q248, Q313, and Q329; the latter has an unusual consensus 
sequence, Asn-X-Cys. Desialylation of PC and factor IX was shown to result in a two-
threefold increase in the anticoagulant activity of protein C and in a loss of the coagulant 
activity of factor IX (Gil et al., 2009; Grinnell et al., 1991). Alterations in the glycosylation 
pattern have been suggested to be specific in certain diseases (An et al., 2009; Ohtsubo & 
Marth, 2006). Nevertheless, it remains unclear whether inflammation signals control 
processing of coagulation proenzymes or not. Well-documented inflammation impact on 
glycosylation of classic APPs allows researchers to suggest such a control. The most 
important mechanism, through which the inflammatory environment is able to alter the 
enzyme activity and/or substrate specificity in local environments or in a systemic disease 
are modifications of the glycan moiety or heterogeneity. Experiments with glycoprotein 
deglycosylation showed that the removal of distinct glycan or total deglycosylation usually 
leads to remarkable reduction of the protein binding and enzymatic activity. However, at 
least two examples have been recently elucidated (Skropeta, 2009), where the enzyme 
activity increased upon deglycosylation of HSPPs. In particular, removal of the two of four 
existing glycosylation sites in the human protein C molecule resulted in a two–threefold 
increase in the anticoagulant activity of APC due to an enhanced affinity of thrombin, the 
natural activator of PC. Interestingly, two fibrinolytic proteins, tPA and its specific substrate, 
Pg, interact more or less effectively depending on the peculiarities of attached glycans. 
Indeed, tPA can exist as two glycoforms, type I with three N-glycosylated sites and type II 
with two N-glycans. Plasminogen also exists in two glycoforms; type 1 has both N- and O-
linked glycans, while type 2 has only an O-linked glycan. The combination of type II tPA 
with type 2 plasminogen induced a twofold more intense conversion of plasminogen to 
plasmin compared to interaction of more heavily glycosylated type I tPA with type 1 Pg. 
Changes in the microheterogenity and unique structure of glycans are now known to be 
ensued from folding of the glycoprotein early form during post-translation processing in the 
secretory pathway. Glycosylation is an enzymatic process regulated by distinct 
glycosyltransferases in the endoplasmic reticulum, which modulate unfolded glycoproteins 
prior to trafficking to the Golgi apparatus. Unexpectedly, one experiment demonstrated that 
an alterated O-glycosylation pathway affects the N-glycosylated coagulation proteins in 
NAcT-1-deficient mice. In particular, the deficiency of a polypeptide GalNAc transferase 
(ppGalNAcT) contributed to shifting of O-glycan repertoire by other glycosyltransferases, as 
well as affected blood coagulation resulting in prolongation of the activated partial 
thromboplastin time, APTT, and bleeding time. These abnormalities were accompanied by 
mild or moderate decreases in the circulating levels of factors V, VII, VIII, IX, X, and XII, 
whereas the level of von Willebrand factor tended to raise (Tenno et al., 2007). The reported 
results might be interpreted as a consequence of pleuotropic effects of O-glycosylation that 
contribute to regulation of HSPP expression and/or turnover (primarily secretion and 
clearance). Additionally, alterations in the degree of branching and of levels of sialylation, 
fucosylation, and mannosylation can dramatically change the glycoprotein turnover. 
Although our information about glycan-mediated pathophysiological mechanisms is still 
very limited, their impact on the enzyme secretion, stability, and activity and on molecular 
trafficking and clearance allows researchers to suggest that glycosylation plays a special role 
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in the phenotypical variability of hemostatic and inflammatory proteins in circulation. 
Apparently, the acute-phase response generates a characteristic protein profile by alteration 
of synthesis, secretion, and clearance of protein reflected in their final concentrations. The 
actual level of plasma proteins under pathological conditions is also determined by changes 
in their stability, post-secretion proteolysis, functional activity, and accessibility for 
interaction.  
Marked alterations in the plasma protein levels are probably paralleled by modifications of 
their disulphide bonds. The role of disulfides in regulation of the functional activity of 
HSPPs was subjected to intense research. A direct influence of inflammatory conditions on 
the structure or functions of plasma proteins is an intriguing question. Recently, we 
demonstrated that the concentration of DTNBA-active polypeptides produced in the course 
of the reaction of plasma and serum proteins with 5,5'-dithiobis(2-nitrobenzoic acid), was 
noticeable increased in patients with stable angina pectoris compared to healthy subjects. In 
vitro blood coagulation was accompanied by a six-fold drop of the SS-containing 
components and 2,5-fold elevation of SH-containing polypeptides in patients, whereas mild 
changes were documented in control subjects. In addition, positive correlation of the plasma 
level of SH-containing polypeptides with concentrations of CRP and low-density 
lipoproteins was observed. Based on our findings, we can speculate that hypercoagulation 
in sclerotized vessels can enhance inflammation by promoting the development of oxidative 
stress. Activated, and thereby, partially degraded HSPPs, after their more open 
conformation has been obtained, can exhibit earlier buried disulphide bridges, which can 
serve as pro-oxidant derivates during thiol-disulfide exchange (Patalakh et al., 2008). Earlier, 
in the study of Procyk and colleagues (1992), it was found that thrombin looses its ability to 
cleave Fg in a calcium-free medium under non-denaturing conditions after reduction of 
several disulfide bonds in ǂ- and Ǆ-chains of fibrinogen. The loss of thrombin clottability 
was suggested to result from perturbation of carboxy-terminal polymerization sites in the 
fibrinogen Ǆ-chain. It is interesting that tPA converted Pg into Pm more effectively on the 
surface of non-clottable (partially reduced) Fg rather than on untreated Fg (Procyk et al., 
1992). These data confirm the statement on the ability of disrupted disulfide bonds to 
modulate the functional activity of major HSPPs via conformational changes. Newly 
obtained data suggest that particular SS-bonds are involved in regulation of HSPP functions 
via reduction or oxidation. Most hemostasis-related proteins probably contain these 
functionally active allosteric disulfide bonds; among them, there are TF, Fg, Pg(Pm), tPA, 
uPA, an uPA receptor, vitronectin, glycoprotein 1bǂ, ß3 subunit of ǂIIbß3 integrin, and 
thrombomodulin (Chen & Hogg, 2006). We hypothesized that at least one common sensitive 
element in the protein structures of the plasma pattern might facilitate the adequate 
integrated response of the hemostasis system to an inflammatory impact. Redox-mediated 
signals, which are generated in plasma during inflammation, might control hemostasis 
pathways via such a sensitive element in protein structures. And vice versa, exposed 
disulfide bonds through one-electron reduction can generate active intermediates 
transmitting pro-inflammatory or pro-oxidant extracellular signals to cell receptors and, 
thus, can induce production of more APPs and HSPPs, especially via the MAPK-mediated 
pathway (Forman et al., 2004; Rees et al., 2008). 
Although HSPPs are synthesised and secreted principally in hepatocytes (Ruminy et al., 
2001) other cell types can be additionally involved. For example, vascular endothelial cells 
represent an almost exclusive source of such a fibrinolytic component, as tPA produced by 
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the endothelium in both physiological and pathophysiological states. Another fibrinolytic 
component, PAI-1, has additional sites of synthesis, such as vascular endothelial cells, 
leukocytes, adipocytes, and platelets, but this occurs predominantly after their activation at 
inflammatory foci. Synthesis of protein C, which mainly occurs in the liver, was also 
identified in the kidneys, lungs, brain, and male reproductive tissue. Therefore, a systemic 
or local inflammatory signal is able to recruit more than one cells source of HSPP. 
Aggregated platelets, activated leukocytes, and cells presented in the vascular wall release 
cytokines thereby altering local HSPP secretion. Impairment of total HSPP production 
because of disorders of the liver functions during systemic inflammation can be 
accompanied by increased protein consumption or by a decrease in the hepatic clearance for 
individual proteins. Perpetuation of inflammation in patients suffering from sepsis is known 
to depress the activity of Pg or ǂ2-plasmin inhibitor (ǂ2-PI) rather because of a low synthetic 
function of the liver but not consumption coagulopathy (Asakura et al., 2001). In contrast, 
increased consumption is the main reason for suppression of the plasma level of such 
enzymatically active proteases, as APC, thrombin, Pm, and tPA. In turn, depletion of the 
pool of proteases results in ineffective consumption and clearance of their substrates. 
Additionally to the protein expression, this mechanism can participate in elevation of such 
hemostatic APPs as factors VIIIa and Va, Fg, Fn, and Pg (Baklaja & Pešic, 2008). Finally, the 
rate of secretion and/or clearance processes of plasma proteins should be markedly distinct 
from the rate of their synthesis. Respectively, the half-life time of involved factors is 
shortened or prolonged.  
It is obvious that the plasma levels of naturally active (e.g., tPA) or in situ activated 
hemostatic proteases (e.g., thrombin or APC) fluctuate during inflammation rather due to 
stimulation of secretion, reactivity, and clearance than due to the respective gene expression 
in the cells. The above-mentioned regulatory mechanisms can affect significantly the HSPP 
kinetic profile with either a rise or a decline of their plasma levels. According to the study of 
Jern and colleagues (Jern et al., 1999), there is no correlation between the net release rate of 
total t-PA and plasma levels of either total or active tPA. These authors also suggested that 
the local endothelial release rate, rather than the systemic plasma level of t-PA, determines 
the plasma fibrinolytic potential destined to clot digestion in situ. The assay-measured 
plasma concentration of tPA insufficiently displays this local discrete increment. Moreover, 
while cytokine-induced PAI-I secretion increases, tPA secretion alternatively decreases (as 
after CRP-regulated secretion) or remains unchanged. Platelets have a large PAI-1 storage 
pool within secretory ǂ-granules (about 90 % of the plasma level). After platelet activation, 
PAI-1 is released from ǂ-granules along with other coagulation proteins, adhesion 
molecules, integrins, growth factors, and inflammatory modulators. Such a pro-
inflammatory milieu facilitates the recruitment of additional platelet and inflammatory cells 
encouraging generate and amplify inflammation signals. Tissue plasminogen activator is 
secreted from the intracellular storage compartment after stimulation of PARs on the surface 
of endothelial cells. There are two pathways involved in tPA secretion from endothelial 
cells, constitutive and regulated secretion. Rates of the constitutive tPA release is 
differentiated markedly by the genotype; however, genetic variation most likely is not 
reflected in the circulating plasma t-PA levels. It was reported that CRP impaired the release 
of tPA via Fc-Ǆ receptors but did not affect tPA mRNA (Devaraj et al., 2005). Stimulation of 
endothelial cells with IL-1ß or TNF-ǂ did not change their ability to produce tPA (Jern et al., 
1999). Shear stress can modulate the cytokine effects by enhancing t-PA secretion and 
attenuating the PAI-1 release (Kawai et al., 1996).  
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Probably, the recovery of the tPA plasma pool in proportion to excessive consumption by 
PAI-1 is rapid but transient, since the augmented local tPA secretion is limited by the rate of 
its synthesis. Because of the fact that the tPA-PAI-1 complex is usually cleared at a lower 
rate than free tPA, this can lead to the appearance of a disproportion between the antigen 
and activity values. Notably, activated protein C is suggested to compete with tPA for PAI-1 
complexation. The importance of APC-PAI-1 in vivo association is still disputable because 
the PAI-1 reactivity with respect to APC is very low in a purified system. Nevertheless, it 
was demonstrated that vitronectin, a pro-inflammatory protein, enhances the reactivity of 
PAI-1 with APC about 300 times (Rezaie, 2001).  
In a study with patients suffering from chronic cardiac failure (CCF) and stable angina 
pectoris (SAP) we found an abnormality of the ratios between the plasma levels of t-PA, PC, 
and PAI-1 (Patalakh et al, 2009; Patalakh et al, 2007). An insufficiency of Ǿǿ and t-PA 
proteins was accompanied by increase in the PAI-1 concentration and activity in the blood 
plasma of patients with high intravascular inflammation (hs-CRP levels were 12,95±1,81 and 
6,83±1,48 mg/ml for SAP and CCF, respectively). We believe that these changes are a 
manifestation of reduction of the blood fibrinolytic potential. Using a regression analytical 
procedure, we simulated a potential profibrinolytic effect of endogenous PC as association 
of its plasma level with PAI-1 attenuation. The effect became apparent within a close-cut 
range of the PAI-1 concentrations and descended at low (<0,8 nM) or high (>3 nM) PAI 
concentrations. It was also predicted that the profibrinolytic function of APC during CCF 
duration might be realized under conditions where the precursor PC concentration did not 
decrease below 50-60 nМ.  
Some evidence do exist that the plasma levels of PC are associated with the systemic 
inflammatory response to trauma, infection, resuscitated cardiac arrest, non-stable angina 
pectoris, etc. It seems that most cardio-vascular diseases during their severe inflammation 
stage are complicated by a transient PC deficiency. The nature of this failure is not 
completely clear. We suppose that the PAI-1 inhibitory activity is involved into PC plasma 
pool depletion during acute inflammation. It seems that phenotypic PC alterations reflect 
different aspects of the APC turnover, up-regulated by inflammation stimuli. It seems that 
conversion of PC into APC, forced by the increasing thrombin production, can lead to rapid 
consumption of PC since APC undergoes action of the abundant amount of serine protease 
inhibitors, accumulated in the blood during the acute-phase response. PAI-1 is the most up-
regulated inhibitor of APC during acute inflammation. Activated platelets additionally 
produce PAI-1 during coagulation and thrombus formation. Particularly due to vitronectin 
activation PAI-1 should contribute significantly to the acquired protein C deficiency. Only 
when present in physiological concentrations, APC can deplete PAI-1 and, thus, promote 
the involvement of t-PA in fibrinolysis. Due to severe or prolonged conversion of PC into 
APC, the plasma pool of PC may be exhausted. As a result, further generation of activated 
protein C will be disturbed. The retarded turnover of protein C (t1/2~ 8 hours) and an 
extremely short clotting time (about 2-3 min) might cause depression of the protein C 
pathway and, consequently, uncontrolled promotion of the thrombin pathway. As a result 
APC loses its crucial role in the regulation of hemostasis and inflammation. While 
coagulation and inflammation are escalated, anticoagulant and fibrinolytic blood potentials 
are dropped. The described progression of events might provoke inflammatory and 
thrombogenic diseases in a manner we illustrate in figure 3. 
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6. Conclusion  
Recent advances in our understanding of the nature of critical factors, linking 
hypercoagulation with both acute and chronic inflammation are rather promising. 
Nevertheless, we only can propose some speculations predicting the balance disruption 
between procoagulant and anticoagulant components under conditions of abnormal 
hemostasis, as well as consequences of their ratio abnormality on inflammation duration. 
The problem is complicated by the existence of poorly predictable mechanisms of most 
urgent thrombotic events that are happened rather “now” and “here”. A transient deficiency 
or acute inactivation of common hemostatic soluble plasma proteins, affecting hemostasis 
and inflammation by a mutual regulatory mechanism, was suggested as a key pathogenic 
factor of such life-threatening complications. Post-translational HSPPs modifications 
reviewed here could be considered as crucial phenomenon impacted by the inflammatory 
process. Apparently, inflammation-associated variations in the structure and function of 
hemostatic proteins can influence their catalytic efficiency and measurable plasma levels. 
These changes should be taken into account in indication of pathological hemostasis. The 
recent knowledge on regulatory crosstalk between hemostatic system components and the 
inflammatory system allows discovering new therapeutic targets to be developed. This new 
approach could not only change the traditional paradigm of clotting factor substitution 
therapy, but also anti-inflammatory therapies. Activated protein C is expected to be an 
attractive therapeutic target with prominent anticoagulant, profibrinolytic, and anti-
inflammatory properties, which can simultaneously regulate both inflammation and 
coagulation. Nevertheless, the results of several clinical trials with recombinant APC or 
modified rAPC were found to be rather disappointing. Indeed, the peculiarities of the 
protein structure, attributed to regulatory components with pleiotropic action such as APC, 
may play a pivotal role in providing clinical benefit of designed protein variants. 
Hemostasis is a thorough “molecular machine”, which can not readily be improved. To 
understand and to reconstruct perturbed functions of this machinery should be a prominent 
goal for both basic and clinical research studies. 
7. Acknowledgment  
The author is thankful to Professor Stanislaw A. Kudinov, Dept. of Enzyme Chemistry and 
Biochemistry (Palladin Institute of Biochemistry of the NAS of Ukraine) for initiating the 
idea of this review. The author would like also thank Professor Francisco Veas for advice 
and for critically reading the manuscript. We acknowledge the financial support from the 
Anisimov Property Management LTD (Ukraine) and from Sergey Davydov, businessman. 
8. References 
Ahamed J., Versteeg H.H., Kerver M., Chen V.M., Mueller B.M., Hogg P.J. & Ruf W. (2006). 
Disulfide isomerization switches tissue factor from coagulation to cell signaling. 
Proc. Nat.l Acad. Sci. USA. Vol. 103, No. 38, pp. 13932-13937. 
An H.J., Kronewitter S.R., de Leoz M.L. & Lebrilla C.B. (2009). Glycomics and disease 
markers. Curr. Opin. Chem. Biol., Vol.13, No (5-6), pp. 601-607. 
Asakura H., Ontachi Y., Mizutani T., Kato M., Ito, T., Saito M., Morishita E., Yamazaki M., 
Suga Y., Miyamoto K.-I. & Nakao S. (2001). Depressed plasma activity of 
www.intechopen.com
 
Hemostatic Soluble Plasma Proteins During Acute-Phase Response and Chronic Inflammation 
 
129 
plasminogen or [alpha]2 plasmin inhibitor is not due to consumption coagulopathy 
in septic patients with disseminated intravascular coagulation. Blood Coagulation & 
Fibrinolysis, Vol.12, Issue 4, pp. 275-281. 
Bae J.S., Yang L., Manithody C.& Rezaie A.R. (2007). The ligand occupancy of endothelial 
protein C receptor switches the PAR-1-dependent signaling specificity of thrombin 
from a permeability-enhancing to a barrier-protective response in endothelial cells. 
Blood, Vol.110, No.12, pp. 3909–3916. 
Baklaja R., M. C. Pešic M. C. & Czarnecki J. (2008). Hemostasis and hemorrhagic disorders. 
Fermentation-Biotec GmbH, ISBN – 978-3-00-025826-8, 337 p. 
Bannach F.G., Guttierez-Fernandez A., Parmer R.J. & Miles L.A. (2004). Interleukin-6-
induced plasminogen gene expression in murine hepatocytes is mediated by 
transcription factor CCAAT/enhancer binding protein ß (C/EBPß). J. Thromb. 
Haemost., 2004, Vol. 2, No.12, pp. 2205–2212.  
Bastarache J.A., Wang L., Wang Z., Albertine K.H., Matthay M.A.& Ware L.B. (2008). Intra-
alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor 
procoagulant activity. Am. J. Physiol. Lung Cell Mol. Physiol., Vol. 294, No.5, pp. L874 
- L881. 
Bevilacqua M.P., Pober J.S., Majeau G.R., Fiers W., Cotran R.S. & Gimbrone M.A.Jr. (1986). 
Recombinant TNF induces procoagulant activity in cultured human vascular 
endothelium: characterization and comparison with the actions of IL-1. Proc. Natl. 
Acad. Sci. U S A. , Vol. 83, No.12, pp.4533– 4537. 
Bisoendial R.J., Kastelein J.J., Levels J.H., Zwaginga J.J., van den Bogaard B., Reitsma P.H., 
Meijers J.C., Hartman D., Levi M. & Stroes ES. (2005). Activation of inflammation 
and coagulation after infusion of C-reactive protein in humans. Circ Res., Vol. 96, 
No. 7, pp. 714-716. 
Blann A.D. & Lip G.Y. (2003). Effects of CRP on the release of von Willebrand factor, E-
selectin, thrombomodulin and intercellular adhesion molecule-1 from HUVEC. 
Blood Coagul. Fibrinolysis, Vol. 14, No. 4, pp. 335–340. 
Busso N., Chobaz-Péclat V., Hamilton J., Spee P., Wagtmann N. & So A. (2008). Essential 
role of platelet activation via protease activated receptor 4 in tissue factor-initiated 
inflammation. Arthritis Res. Ther., Vol. 10, No.2, R42.  
Butenas S., Orfeo T. & Mann K.G. (2009). Tissue Factor in Coagulation: Which? Where? 
When? Arterioscler. Thromb. Vasc. Biol., Vol. 29, No.12, pp. 1989-1996. 
Calabrò P., Golia E. & Yeh E.T. (2009). CRP and the risk of atherosclerotic events. Semin. 
Immunopathol., Vol. 31, No.1, pp. 79-94.  
Castellheim A., Brekke O.L., Espevik T., Harboe M. & Mollnes T.E. (2009). Innate immune 
responses to danger signals in systemic inflammatory response syndrome and 
sepsis. Scand. J. Immunol., Vol. 69, No. 6, pp.479-491. 
Cermak J., Key N.S., Bach R.R., Balla J., Jacob H.S. & Vercellotti G.M. (1993). CRP induces 
human peripheral blood monocytes to synthesize tissue factor. Blood, Vol. 82, pp. 
513–520. 
Chavakis T., Athanasopoulos A., Rhee J.S., Orlova V., Schmidt-Wöll T., Bierhaus A., May 
A.E., Celik I., Nawroth P.P. & Preissner K.T. (2005). Angiostatin is a novel anti-
inflammatory factor by inhibiting leukocyte recruitment. Blood, Vol.105, No. 3, pp. 
1036-1043.  
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
130 
Chen C., Nan B., Lin P. & Yao Q. (2008). C-reactive protein increases plasminogen activator 
inhibitor-1 expression in human endothelial cells. Thrombosis Research, Vol. 122, No. 
1, pp. 125-133. 
Chen V.M. & Hogg P.J. (2006). Allosteric disulfide bonds in thrombosis and thrombolysis. J. 
Thromb. Haemost. Vol. 4, No. 12, pp. 2533-2541. 
Cheng T., Mathews K. A., Abrams-Ogg A.C.G. & Wood R. D. (2009). Relationship between 
assays of inflammation and coagulation: A novel interpretation of the canine 
activated clotting time. The Canadian Journal of Veterinary Research., Vol. 73, No. 2, 
pp. 97–102. 
Chua A.J. (2005). Tissue factor mediates inflammation. Archives of Biochemistry and Biophysics, 
Vol. 440, No. 2, pp. 123-132. 
Corti R., Fuster V. & Badimon J.J. (2003). Pathogenetic concepts of acute coronary 
syndromes. J. Am. Coll. Cardiol., Vol. 41, No. 4 , pp. 7S-14S. 
Cruz-Topete D., Iwaki T., Ploplis V.A.& Castellino F.J. (2006). Delayed inflammatory 
responses to endotoxin in fibrinogen-deficient mice. The Journal of Pathology, Vol. 
210, No. 3, pp. 325–333 
Cunningham M.A., Romas P., Hutchinson P., Holdsworth S. R. & Tipping P.G. (1999). 
Tissue factor and factor VIIa receptor/ligand interactions induce proinflammatory 
effects in macrophages. Blood, Vol. 94, No.10, pp. 3413 - 3420. 
Dahlback B. (1991). Protein S and C4b-binding protein: components involved in the 
regulation of the protein C anticoagulant system. Thromb. Haemost., Vol. 66, No. 1, 
pp. 49-61. 
Danese S., Vetrano S., Zhang L., Poplis V.A. & Castellino F.J. (2010). The protein C pathway 
in tissue inflammation and injury: pathogenic role and therapeutic implications. 
Blood, Vol. 115, No. 6, pp. 1121–1130. 
de Ferranti S.D., & Rifai N. (2007). C-reactive protein: a nontraditional serum marker of 
cardiovascular risk. Cardiovasc. Pathol., Vol. 16, No. 1, pp. 14-21. 
de Waal M.R., Abrams J., Bennett B., Figdor C.G., & de Vries J.E. (1991). Interleukin 10(IL-10) 
inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 
produced by monocytes. J. Exp. Med., Vol.174, No.5, pp. 1209–1220. 
DelGiudice L.A. & White G.A. (2009). The role of tissue factor and tissue factor pathway 
inhibitor in health and disease states. J. Vet. Emerg. Crit. Care (San Antonio), Vol. 19. 
No. 1, pp. 23-29. 
Devaraj S., Du Clos T.W. & Jialal I. (2005). Binding and internalization of CRP by Fc gamma 
receptors on human aortic endothelial cells mediates biological effects. Arterioscler. 
Thromb. Vasc. Biol., Vol.25, No.7, pp. 1359–1363. 
Devaraj S., Xu D.Y. & , Jialal I. (2003). C-reactive protein increases plasminogen activator 
inhibitor-1 expression and activity in human aortic endothelial cells: implications 
for the metabolic syndrome and atherothrombosis. Circulation, Vol. 107, No.3, pp. 
398–404. 
Egorina E.M., Sovershaev M.A., Bjorkoy G., Gruber F.X., Olsen J.O., Parhami-Seren B., Mann 
K.G. & Osterud B. (2005). Intracellular and surface distribution of monocyte tissue 
factor: application to intersubject variability. Arterioscler. Thromb. Vasc. Biol., Vol. 25, 
No. 7, pp. 1493-1498. 
Erlich J.H., Boyle E.M., Labriola J., Kovacich J.C., Santucci R.A., Fearns C., Morgan E.N., Yun 
W., Luther T., Kojikawa O., Martin T.R., Pohlman T.H., Verrier E.D. & Mackman N. 
www.intechopen.com
 
Hemostatic Soluble Plasma Proteins During Acute-Phase Response and Chronic Inflammation 
 
131 
(2000). Inhibition of the tissue factor-thrombin pathway limits infarct size after 
myocardial ischemia-reperfusion injury by reducing inflammation. Am. J. Pathol., 
Vol. 157, No. 6, pp. 1849–1862. 
Esmon C.T. (2004). Crosstalk between inflammation and thrombosis. Maturitas, Vol. 47, No. 
4, pp. 305-314.  
Esmon ǿ.T. (2005). The interactions between inflammation and coagulation. Br. J. Haematol., 
Vol. 131, No. 4, pp. 417-430. 
Feistritzer C.& Riewald M. (2005). Endothelial barrier protection by activated protein C 
through PAR1-dependent sphingosine 1–phosphate receptor-1 crossactivation. 
Blood, Vol.105, No.8, pp. 3178–3184. 
Flick M.J., Du X. & Degen J.L. (2004). Fibrin(ogen)-ǂMß2 interactions regulate leukocyte 
function and innate immunity in vivo. Exp. Biol. Med., Vol. 229, pp. 1105–1110. 
Flick M.J., LaJeunesse C.M., Talmage K.E., Witte D.P., Palumbo J.S., Pinkerton M.D., 
Thornton S. & Degen J.L. (2007). Fibrin(ogen) exacerbates inflammatory joint 
disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J. 
Clin. Invest., Vol. 117, No.11, pp. 3224-3235. 
Forman H.J., Fukuto J.M.& Torres M. (2004). Redox signaling: thiol chemistry defines which 
reactive oxygen and nitrogen species can act as second messengers. Am. J. Physiol. 
Cell Physiol., Vol.287, No.2, pp. C246-C256. 
Gabay C. & Kushner I. (2001). Acute-phase proteins. Encyclopedia of Life Sciences. 
Available from: onlinelibrary.wiley.com/doi/ 10.1038/npg.els.0000497/pdf. 
Gabay C. & Kushner I.(1999). Acute-phase proteins and other systemic responses to 
inflammation. N. Engl. J. Med., Vol. 340, No.6, pp. 448 – 454. 
Gil G.C., Velander W.H. & Van Cott K.E. (2009). N-glycosylation microheterogeneity and 
site occupancy of an Asn-X-Cys sequon in plasma-derived and recombinant protein 
C. Proteomics., Vol. 9, No.9, pp. 2555-2567. 
Grinnell B.W., Walls J.D. & Gerlitz B. (1991). Glycosylation of human protein C affects its 
secretion, processing, functional activities, and activation by thrombin. J. Biol. 
Chem., Vol. 266, No. 15, pp. 9778-9785. 
Guitton C., Cottereau A., Gérard N., Quillard T., Chauveau A., Devallière J., Tonnerre P. & 
Charreau B. (2011). Protective cross talk between activated protein C and TNF 
signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-κB, 
and ERK1/2 MAP kinases. Am. J. Physiol. Cell Physiol., Vol. 300, No. 4, pp. C833-
C842. 
Guo F., Liu J., Wang C., Liu N. & Lu P. (2009). Fibrinogen, fibrin, and FDP induce C-reactive 
protein generation in rat vascular smooth muscle cells: Pro-inflammatory effect on 
atherosclerosis. Biochemical and Biophysical Research Communications, Volume 390, 
Issue 3, pp. 942-946. 
Hattory M., Abraham L.J., Northemmann W. & Fey G.H. (1990). Acute-phase reaction 
induces a specific complex between hepatic uclear proteins and the interleukin 6 
response element of the rat a2-macroglobulin gene. Proc. Natl. Acad. Sci. USA, Vol. 
87, No. 6,pp. 2364-2368. 
Hezi-Yamit A., Wong P.W., Bien-Ly N., Komuves L.G., Prasad K.S.S., Phillips D.R. & Sinha 
U. (2005). Synergistic induction of tissue factor by coagulation factor Xa and TNF: 
Evidence for involvement of negative regulatory signaling cascades. PNAS, Vol. 
102, No. 34, pp. 12077–12082. 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
132 
Himber J., Wohlgensinger C., Roux S., Damico L.A., Fallon J.T., Kirchhofer D., Nemerson Y., 
Riederer M.A. (2003). Inhibition of tissue factor limits the growth of venous 
thrombus in the rabbit. J.Thromb. Haemost., Vol. 1, No. 5, pp. 889–895. 
Hou T., Tieu B.C., Ray S., Recinos 3d A., Cui R., Tilton R.G. & Brasier A.R. (2008). Roles of 
IL-6-gp130 signaling in vascular inflammation. Current Cardiology Reviews, Vol. 4, 
No.3, pp. 179-192. 
Jennewein C., Tran N., Paulus P., Ellinghaus P., Eble J.A.& Zacharowski K. (2011). Novel 
aspects of fibrin(ogen) fragments in the course of inflammation. Molecular medicine 
(Cambridge, Mass.). (In press). 
Jensen T., Kierulf P., Sandset P.M., Klingenberg O., Joø G.B., Godal H.C. & Skjønsberg O.H.  
(2007). Fibrinogen and fibrin induce synthesis of proinflammatory cytokines from 
isolated peripheral blood mononuclear cells. Thromb. Haemost., Vol. 97 No.5, pp. 
822-829. 
Jern C., Ladenvall P., Wall U. & Jern S. (1999). Gene polymorphism of t-PA is associated 
with forearm vascular release rate of t-PA. Arterioscler. Thromb. Vasc. Biol., Vol. 19, 
No. 2, pp. 454–459.  
Jiang S.-L., Samols D., Rzewnicki D., Macintyre S.S., Greber I., Sipe J. & Kushne I. (1995). 
Kinetic modeling and mathematical analysis indicate that acute phase gene 
expression in Hep 3B cells is regulated by both transcriptional and 
posttranscriptional mechanisms. J. Clin. Invest., Vol. 95, No.3, pp. 1253-1261. 
Joyce D.E., Gelbert L., Ciaccia A., DeHoff B.& Grinnell B.W. (2001). Gene expression profile 
of antithrombotic protein C defines new mechanisms modulating inflammation 
and apoptosis. J.Biol.Chem., Vol. 276, No.14, pp. 11199-1203.  
Kasza A., Kiss D.L., Gopalan S., Xu W., Rydel R.E., Koj A. & Kordula T. (2002). Mechanism 
of plasminogen activator inhibitor-1 regulation by oncostatin M and interleukin-1 
in human astrocytes. Journal of Neurochemistry, Vol. 83, No.3, pp. 696–703. 
Kawai Y., Matsumoto Y., Watanabe K., Yamamoto H., Satoh K., Murata M., Handa M. & 
Ikeda Y. (1996). Hemodynamic forces modulate the effects of cytokines on 
fibrinolytic activity of endothelial cells. Blood, Vol. 87, No. 6, pp. 2314-2321. 
Kushner I. & Rzewnicki D.L. (1994). The acute phase response: General aspects. Bailliére' s 
Clinical Rheumatology, Vol. 8, No. 3, pp. 513-530.  
Levi M. & Poll T. (2008). The role of natural anticoagulants in the pathogenesis and 
management of systemic activation of coagulation and inflammation in critically ill 
patients. Semin. Thromb. Hemost., Vol. 34, No.5, pp. 459-468. 
Levi M., van der Poll T. & Buller H.R. (2004). Bidirectional relation between inflammation 
and coagulation. Circulation, Vol. 109, No.22, pp. 2698–2704. 
Liaw P.C., Neuenschwander P.F., Smirnov M.D. & Esmon C.T. (2000). Mechanisms by 
which soluble endothelial cell protein C receptor modulates protein C and 
activated protein C function. J. Biol. Chem., Vol. 275, No.8, pp. 5447-5452. 
Lindmark E., Tenno T.& Siegbahn A. (2000). Role of platelet P-selectin and CD40 ligand in 
the induction of monocytic tissue factor expression. Arterioscler. Thromb. Vasc. Biol., 
Vol. 20, No. 10, pp. 2322-2328. 
Loppnow H. & Libby P. (1990). Proliferating or interleukin 1-activated human vascular 
smooth muscle cells secrete copious interleukin 6. J. Clin. Invest., Vol. 85, No.3, pp. 
731–738. 
www.intechopen.com
 
Hemostatic Soluble Plasma Proteins During Acute-Phase Response and Chronic Inflammation 
 
133 
Lowry S.F. (2009). The evolution of an inflammatory response. Surg. Infect. (Larchmt), Vol. 
10, No. 5, pp. 419-425. 
Luther T., Dittert D.D., Kotzsch M., Erlich J., Albrecht S., Mackman N. & Muller M. (2000). 
Functional implications of tissue factor localization to cell-cell contacts in 
myocardium. J. Pathol., Vol. 192, No. 1, pp. 121–130. 
MacCallum P.K. (2005). Markers of hemostasis and systemic inflammation in heart disease 
and atherosclerosis in smokers. Proc. Am. Thorac. Soc., Vol. 2, No.1, pp. 34-43. 
Macfelda K., Weiss T. W., Kaun C., Breuss J.M., Kapeller B., Zorn G., Oberndorfer U., 
Voegele-Kadletz M., Huber-Beckmann R., Ullrich R., Binder B. R., Losert U. M., 
Maurer G., Pacher R., Huber K. & Wojta J. (2002). Plasminogen activator inhibitor 1 
expression is regulated by the inflammatory mediators interleukin-1ǂ, tumor 
necrosis factor-ǂ, transforming growth factor-ß and oncostatin M in human cardiac 
myocytes. J. Mol. Cell. Cardiol., Vol. 34, No. 12, pp. 1681-1691.  
Mackiewicz A., Speroff T., Ganapathi M.K. & Kushner I. (1991). Effects of cytokine 
combinations on acute phase protein production in two human hepatoma cell lines. 
J. Immunol., Vol.146, No.9, pp. 3032-3037. 
Manukyan D., von Bruehl M.L., Massberg S. & Engelmann B. (2008). Protein disulfide 
isomerase as a trigger for tissue factor-dependent fibrin generation. Thromb. Res., 
No. 122, Suppl. 1, pp. S19-22. 
Markiewski M.M., Nilsson B., Ekdahl K.N., Mollnes T.E. & Lambris J.D. (2007). Complement 
and coagulation: strangers or partners in crime? Trends Immunol. Vol. 28, No.4, pp. 
184-192. 
McClure D.B., Walls J.D. & Grinnell B.W. (1992). Post-translational processing events in the 
secretion pathway of human protein C, a complex vitamin K-dependent 
antithrombotic factor. J. Biol. Chem., Vol. 267, No.27, pp. 19710-19717. 
Medcalf R.L. (2007). Fibrinolysis, inflammation, and regulation of the plasminogen 
activating system. J.Thromb. Haemost., Vol. 5, Suppl 1, pp. 132–142. 
Meltzer M.E., Doggen C. J. M., de Groot P. G., Rosendaal F. R. & Lisman T. (2010). Plasma 
levels of fibrinolytic proteins and the risk of myocardial infarction in men Blood., 
Vol.116, No.4, pp. 529-536. 
Monaco C., Andreakos E., Young S., Feldmann M. & Paleolog E. (2002). T cell-mediated 
signaling to vascular endothelium: induction of cytokines, chemokines, and tissue 
factor. J. Leukoc. Biol., Vol. 71, No. 4, pp. 659–668. 
Morley J.J. & Kushner I. (1982) Serum C-reactive protein levels in disease. Annals of the New 
York Academy of Sciences, Vol. 389, pp. 406–418. 
Ohtsubo K. & Marth J.D. (2006). Glycosylation in Cellular Mechanisms of Health and 
Disease. Cell, Vol. 126, No. 5, pp. 855-867. 
Okada H., Woodcock-Mitchell J., Mitchell J., Sakamoto T., Marutsuka K., Sobel B.E. & Fujii 
S. (1998). Induction of plasminogen activator inhibitor type 1 and type 1 collagen 
expression in rat cardiac microvascular endothelial cells by interleukin-1 and its 
dependence on oxygen-centered free radicals. Circulation., Vol. 97, No. 21, pp. 2175-
2182. 
Owens A.P. 3rd & Mackman N. (2010). Tissue factor and thrombosis: The clot starts here. 
Thromb. Haemost., Vol. 104, No. 3, pp. 432-439.  
Patalakh I.I., Lutai M.I., Gavrilenko T.I., Lomanovsky O.N., Kornilina Ye.M., Shkrabak M.A. 
& Kudinov S.A. (2007) Activity of the fibrinolytic system in patients with stable 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
134 
angina pectoris with signs of inflammation. Laboratory diagnostics (Ukraine), Vol. 4, 
No. 42, pp. 14 -19. 
Patalakh I.I., Ryabenko D.V., Kornilina E.M. & Kudinov S.А. (2009). Protein C in regulation 
of blood plasma fibrinolytic potential in patients with chronic heart failure. 
Circulation and haemostasis (Ukraine), Vol. 3-4, pp. 93-101. 
Patalakh I.I., Urvant L.P., Yevstratova I.N., Drobotko T.F.& Lomakovsky O.M. (2008). 
Plasma protein thiol/disulfides: the role in atherogenesis. Laboratory diagnostics 
(Ukraine), Vol. 4, No. 46, pp. 11-19. 
Perri S. R., Martineau D., François M., Lejeune L., Bisson L., Durocher Y. & Galipeau J. 
(2007). Plasminogen Kringle 5 blocks tumor progression by antiangiogenic and 
proinflammatory pathways. Molecular Cancer Therapeutics, Vol. 6, No. 2, pp. 441–
449. 
Popescu N.I., Lupu C. & Lupu F. (2010) Role of PDI in regulating tissue factor: FVIIa 
activity. Thromb. Res., Vol. 125, Suppl 1, pp. S38-41.  
Procyk R., Medved L., Engelke K.J., Kudryk B.& Blombäck B. (1992). Nonclottable fibrin 
obtained from partially reduced fibrinogen: characterization and tissue 
plasminogen activator stimulation. Biochemistry, Vol. 31, No. 8, pp. 2273–2278. 
Qi J., Goralnick S.& Kreutzer D.L. (1997). Fibrin regulation of interleukin-8 gene expression 
in human vascular endothelial cells. Blood, Vol., No.90, pp. 3595-3602. 
Rao L.V.& Pendurthi U.R. (2005). Tissue factor-factor VIIa signaling. Arterioscler. Thromb. 
Vasc. Biol., Vol. 25, No. 1, pp. 47-56. 
Rees M.D., Kennett E.C., Whitelock J.M.& Davies M.J. (2008). Oxidative damage to 
extracellular matrix and its role in human pathologies. Free Radic. Biol. Med., Vol. 
44, No.12, pp. 1973-2001.  
Rezaie A.R. (2001). Vitronectin functions as a cofactor for rapid inhibition of activated 
protein C by plasminogen activator inhibitor-1. J. Biol. Chem., Vol. 276, No. 19, pp. 
15567-15570. 
Riewald M. & Ruf W. (2001). Mechanistic coupling of protease signaling and initiation of 
coagulation by tissue factor. Proc. Natl. Acad. Sci. U S A., Vol. 98, No. 14, pp. 7742-
7747.  
Ruminy P., Gangneux C., Claeyssens S., Scotte M., Daveau M. & Salier J.P. (2001). Gene 
transcription in hepatocytes during the acute phase of a systemic inflammation: 
from transcription factors to target genes. Inflamm. Res.., Vol. 50, No. 8, pp. 383-390. 
Sarangi P.P., Lee H.W., Kim M. Activated protein C action in inflammation. (2010). Br. J. 
Haematol. , Vol.148, No. 6, pp. 817-33. 
Sardo M.A., Campo S., Mandraffino G, Saitta C., Bonaiuto A., Castaldo M., Cinquegrani M., 
Pizzimenti G. & Saitta A. (2008). Tissue factor and monocyte chemoattractant 
protein-1 expression in hypertensive individuals with normal or increased carotid 
intima-media wall thickness. Clin. Chem., Vol. 54, No. 5, pp. 814-823. 
Schrauwen Y., de Vries R.E.M., Kooistra T. & Emeis J.J. (1994). Acute release of tissue-type 
plasminogen activator (t-PA) from the endothelium; regulatory mechanisms and 
therapeutic target. Fibrinolysis, Vol. 8, Suppl. 2, pp. 8 –12. 
Singh U., Devaraj S. & Jialal I. (2005). C-reactive protein decreases tissue plasminogen 
activator activity in human aortic endothelial cells: evidence that protein is a 
procoagulant. Arterioscler. Thromb. Vasc. Biol., Vol. 25, No. 10, pp. 2216-2221. 
www.intechopen.com
 
Hemostatic Soluble Plasma Proteins During Acute-Phase Response and Chronic Inflammation 
 
135 
Sitrin R.G., Pan, P.M., Srikanth, S.& Todd, R.F., 3rd. (1998). Fibrinogen activates NF-kappa B 
transcription factors in mononuclear phagocytes. J. Immunol., Vol.161, No.3, pp. 
1462-1470. 
Skropeta D. (2009). The effect of individual N-glycans on enzyme activity. Bioorg. Med. 
Chem., Vol.17, No.7, pp. 2645–2653. 
Sommeijer D.W., Hansen H.R., van Oerle R., Hamulyak K., van Zanten A.P., Meesters E., 
Spronk H.M. & ten Cate H. (2006). Soluble tissue factor is a candidate marker for 
progression of microvascular disease in patients with Type 2 diabetes. J. Thromb. 
Haemost., Vol. 4, No. 3, pp. 574-580.  
Spronk H.M.H., Govers-Riemslag J.W.P. & Cate H. (2003). The blood coagulation system as 
a molecular machine. BioEssays, Vol. 25, No. 12, pp. 1220–1228. 
Stephenson D.A, Toltl., L.J., Beaudin S., & Liaw P. C. (2006). Modulation of monocyte 
function by activated protein C, a natural anticoagulant. J. Immunol., Vol. 177, No.4, 
pp. 2115–2122. 
Tamam Y., Iltumur K. & Apak I. (2005). Assesment of acute phase proteins in acute ischemic 
stroke. J. Exp. Med., Vol. 206, No. 2, pp. 91-98.  
Tanaka K.A., Key N. S. & Levy J. H. (2009). Blood coagulation: hemostasis and thrombin 
regulation. Anesth. Analg., Vol. 108., No. 5, pp. 1433–1446. 
Tenno M., Ohtsubo K., Hagen F.K., Ditto D., Zarbock A., Schaerli P., von Andrian U.H., Ley 
K., Le D., Tabak L.A. & Marth J.D. (2007). Initiation of protein O glycosylation by 
the polypeptide GalNAcT-1 in vascular biology and humoral immunity. Mol. Cell 
Biol., Vol. 27, No. 24, pp. 8783-8796. 
Toltl L.J., Beaudin S. & Liaw P.C. (2008). Activated protein C up-regulates IL-10 and inhibits 
tissue factor in blood monocytes. J. Immunol., Vol. 181, No. 3, pp. 2165-2173. 
Trautwein C., Böker K. & Manns M.P. (1994). Hepatocyte and immune system: acute phase 
reaction as a contribution to early defence mechanisms. Gut, Vol. 35, No. 9, pp. 
1163-1166. 
Trezzini C., Schüepp B., Maly F.E. & Jungi T.W. (1991). Evidence that exposure to fibrinogen 
or to antibodies directed against Mac-1 (CD11b/CD18; CR3) modulates human 
monocyte effector functions. Br. J. Haematol., Vol. 77, No. 1, pp. 16-24. 
Van Dijk W. & Mackiewicz A. (1995). Interleukin-6-type cytokine-induced changes in acute 
phase protein glycosylation. Ann. N. Y. Acad. Sci.., Vol. 762, pp. 319-330. 
Viles-Gonzalez J.F., Fuster V. & Badimon J.J. (2005). Thrombin/inflammation paradigms: a 
closer look at arterial and venous thrombosis. Am. Heart J., No. 149, pp. (1 Suppl): 
S19-S31. 
Voetsch В. & Loscalzo J. (2004). Genetic determinants of arterial thrombosis. Arterioscler. 
Thromb. Vasc. Biol., Vol. 24, No. 2, pp. 216-229. 
Walley K.R., Lukacs N.W., Standiford T.J., Strieter R.M. & Kunkel S.L. (1996). Balance of 
inflammatory cytokines related to severity and mortality of murine sepsis. Infect. 
Immun., Vol. 64, No. 11, pp. 4733–4738. 
White B., Schmidt M., Murphy C., Livingstone W., O’Toole D., Lawler M., O’Neill L., 
Kelleher D., Schwarz H. P. & Smith O. P. (2000). Activated protein C inhibits 
lipopolysaccharide-induced nuclear translocation of nuclear factor kB (NF-kB) and 
tumour necrosis factor ǂ (TNF-ǂ) production in the THP-1 monocytic cell line. Br. J. 
Haematol., Vol. 110, Issue 1, pp. 130–134. 
www.intechopen.com
 
Acute Phase Proteins – Regulation and Functions of Acute Phase Proteins 
 
136 
Wiinberg B., Jensen A.L., Johansson P.I., Rozanski E., Tranholm M.& Kristensen A.T. (2008). 
Thromboelastographic evaluation of hemostatic function in dogs with 
disseminated intravascular coagulation. J.Vet. Intern. Med., Vol. 22, No. 2, pp. 357–
365. 
Willerson J.T.& Ridker P.M. (2004). Inflammation as a cardiovascular risk factor. Circulation, 
Vol.109, 21 Suppl1 II-2-II-10.  
Wojta J., Zoellner H., Gallicchio M., Filonzi E.L., Hamilton J.A. & McGrath K. (1994). 
Interferon-alpha 2 counteracts interleukin-1 alpha-stimulated expression of 
urokinase-type plasminogen activator in human foreskin microvascular endothelial 
cells in vitro. Lymphokine Cytokine Res., Vol. 13, No. 2, pp. 133-138. 
Yamamoto K., Shimokawa T., Kojima T., Loskutoff D. J. & Saito H. (1999). Regulation of 
murine protein C gene expression in vivo: effects of tumor necrosis factor-alpha, 
interleukin-1, and transforming growth factor-beta. Thrombosis and Haemostasis, Vol. 
82, No. 4, pp. 1207-1379. 
Zouaoui Boudjeltia K., Piagnerelli M., Brohee D., Guillaume M., Cauchie P., Vincent J.L., 
Remacle C., Bouckaert Y. & Vanhaeverbeek M. (2004). Relationship between CRP 
and hypofibrinolysis: Is this a possible mechanism to explain the association 
between CRP and outcome in critically ill patients? Thromb. J., Vol. 2, No. 1, pp. 7–
12. 
www.intechopen.com
Acute Phase Proteins - Regulation and Functions of Acute Phase
Proteins
Edited by Prof. Francisco Veas
ISBN 978-953-307-252-4
Hard cover, 368 pages
Publisher InTech
Published online 03, October, 2011
Published in print edition October, 2011
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
The two volumes of Acute Phase Proteins book consist of chapters that give a large panel of fundamental and
applied knowledge on one of the major elements of the inflammatory process during the acute phase
response, i.e., the acute phase proteins expression and functions that regulate homeostasis. We have
organized this book in two volumes - the first volume, mainly containing chapters on structure, biology and
functions of APP, the second volume discussing different uses of APP as diagnostic tools in human and
veterinary medicine.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Irina I. Patalakh (2011). Hemostatic Soluble Plasma Proteins During Acute-Phase Response and Chronic
Inflammation, Acute Phase Proteins - Regulation and Functions of Acute Phase Proteins, Prof. Francisco Veas
(Ed.), ISBN: 978-953-307-252-4, InTech, Available from: http://www.intechopen.com/books/acute-phase-
proteins-regulation-and-functions-of-acute-phase-proteins/hemostatic-soluble-plasma-proteins-during-acute-
phase-response-and-chronic-inflammation
© 2011 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
